Inventors list

Assignees list

Classification tree browser

Top 100 Inventors

Top 100 Assignees


Diagnostic or test agent produces in vivo fluorescence

Subclass of:

424 - Drug, bio-affecting and body treating compositions

424900100 - IN VIVO DIAGNOSIS OR IN VIVO TESTING

Patent class list (only not empty are listed)

Deeper subclasses:

Class / Patent application numberDescriptionNumber of patent applications / Date published
424900610 Porphyrin or derivative thereof 17
Entries
DocumentTitleDate
20110177003PROTEINS THAT FLUORESCE AT INFRARED WAVELENGTHS OR GENERATE SINGLET OXYGEN UPON ILLUMINATION - This invention provides novel truncation mutants of a phytochrome from the bacterium 07-21-2011
20080247958Albumin-based colloid composition having at least one protected thiol region, methods of making, and methods of use - A composition comprising an albumin-based colloid composition having at least one protected thiol region, method of making the same, and method for use, including treating hypovolemic conditions such as capillary leak syndrome and shock, are disclosed. The composition also is modified with an indicator reagent such as chromophores.10-09-2008
20090196828CONTRAST AGENT COMPRISING A TM2+ CONTAINING LUMINESCENT SUBSTANCE FOR OPTICAL IMAGING - The invention relates to a contrast agent for optical imaging. The inventive contrast agent comprises a luminescent substance, wherein the luminescent substance comprises Tm08-06-2009
20100061936UNNATURAL AMINO ACIDS CAPABLE OF COVALENTLY MODIFYING PROTEIN PHOSPHATASES AND THEIR USE AS GENERAL AND SPECIFIC INHIBITORS AND PROBES - An unnatural amino acid including a phosphate mimicking group for mimicking a phosphate group in phosphoamino acids and a protein phosphatase modifying group for covalently binding protein phosphatases. A probe for detecting disease including a phosphate mimicking group for mimicking a phosphate group in phosphoamino acids and a protein phosphatase modifying group for covalently binding protein phosphatases. A method for detecting the presence of disease by administering the unnatural amino acid, binding the unnatural amino acid with a phosphatase, detecting a signal, and detecting the presence of disease. A method of identifying a known protein phosphatase, and a method of identifying an unknown protein phosphatase. A method of making the unnatural amino acid.03-11-2010
20100008861WATER SOLUBLE QUANTUM DOTS - An economic, direct synthetic method for producing water soluble QDs that are ready for bioconjugation is provided. The method can produce aqueous QDs with emission wavelengths varying from 400 nm to 700 nm Highly luminescent metal sulfide (MS) QDs are produced via an aqueous synthesis route. MS QDs are capped with thiol-containing charged molecules in a single step. The resultant MS QDs exhibit the distinctive excitonic photoluminescence desired of QDs and can be fabricated to avoid undesirable broadband emissions at higher wavelengths. This provides a significant improvement over the present complex and expensive commercial processes for the production of QDs. The aqueous QDs are stable in biological fluids over a long period of time. In addition, nontoxic ZnS QDs have been produced with good photoluminescence properties by refluxing the ZnS QD suspensions over a period of time.01-14-2010
20090123383Non-Isotopic Detection of Osteoblastic Activity In Vivo Using Modified Bisphosphonates - The present invention is directed to a non-isotopic methods for the in vitro and in vivo detection of hydroxyapatite-positive cells and structures.05-14-2009
20090123381IMAGING AND THERAPEUTIC TARGETING OF PROSTATE AND BLADDER TISSUES - The present invention provides methods for imaging and the treatment of cancer. In certain embodiments, a polyarginine (e.g., R11) may be used to selectively image prostate or bladder cells (e.g., a metastatic prostate cancer). In other embodiments, a DOC-2/DAB2 peptide, optionally conjugated to a cell permeable peptide (e.g., R11) may be used to treat a cancer, such as prostate cancer.05-14-2009
20110195029FLUORESCENT EMULSION - The invention relates to a fluorescent emulsion, to its uses and to labelling reagents comprising it.08-11-2011
20090252687ASYMMETRIC FLUORO-SUBSTITUTED POLYMETHINE DYES - The present invention relates to improved conjugates of biological molecules with an improved class of water-soluble, green to near infra-red (NIR) cyanine labelling dyes. The dyes are asymmetric fluoro-substituted polymethines, and exhibit a high degree of photostability and reduced dye-dye quenching, as well as a high fluorescence quantum yield. The conjugates are useful for in vivo optical imaging, as well as fluorescence detection methods. Also disclosed are pharmaceutical compositions containing the conjugates, kits for the preparation of such compositions, and methods of in vivo imaging using the conjugates.10-08-2009
20120244078OPTICAL IMAGING CONTRAST AGENTS AND USES THEREOF - The invention relates to microbubble contrast agent compositions comprising a gas core encapsulated by a monolayer shell, said shell comprising a first surfactant, a second surfactant having a higher water solubility than said first surfactant, an anchor molecule attached to said shell at the gas-shell interface and an optically-active probe, said probe being detectable by fluorescence, near-infrared, bioluminescence, or other optical imaging methods. Uses of the described compositions for imaging and therapeutic applications are contemplated.09-27-2012
20130078188ACTIVATABLE CELL PENETRATING PEPTIDES WITH QUENCHED FLUOROPHORES - The invention provides compositions useful as molecular probes. In particular, the invention provides activatable cell penetrating peptides comprising a fluorescence donor and a fluorescence acceptor. Exemplary fluorescence donors and fluorescence acceptors include compounds derived from cyanine. Also provided are ratiometric, multispectral, and excitation lifetime imaging methods for detecting the molecular probes provided herein.03-28-2013
20090155183Sensors for the detection of diols and carbohydrates - The systems and methods disclosed herein include a sensor particle for detecting the presence of a chelatable analyte, such as glucose, wherein the sensor comprises a chromophore and a fluorescent component, such as a quantum dot. The sensor particle further comprises moieties that bind both a clelatable analyte and chromophore reversibly and competitively. In the presence of the chelatable analyte, the moieties bind the analyte, and release the chromophore. The chromophore absorbs photons of one wavelength in a free state but of a different wavelength in a bound state, and is selected to operate with the fluorescent component such that the chromophore absorbs emissions of the fluorescent substance in only one of the bound and unbound states. In certain aspects, the invention comprises methods for detecting the presence of a chelatable analyte in a medium such as water, blood plasma and urine, using the sensor particles of the invention.06-18-2009
20090081129Bioluminescent Endoscopy Methods And Compounds - Bioluminescent endoscopy methods and compounds, wherein an anatomical object is examined by means of filling, perfusing, intubating, injecting, or otherwise administering a solution containing a bioluminescent substance or a mixture of luciferin and luciferase which produces bioluminescence, wherein a color or monochrome image of the object is constituted using the images and information based on bioluminescent emitted by the bioluminescent substance. Procedures are demonstrated which allow bioluminescent solutions to be perfused into certain tissue regions, such as but not limited to the common biliary duct, genitourinary tract, gastro-intestinal tract, cardiovascular system and lymphatic system wherein said structures may be conveniently visualized during surgery to avoid damage to these structures. Such images may also be combined with visual light images. Methods of detection of cancer cells using bioluminescence are provided. Preferred embodiments disclosed include membrane permeant coelenterazine analogs.03-26-2009
20080206148Method for radiographic targeting of malignant tumors and apparatus for focusing rays - A method and apparatus for immunoimaging and destruction of malignant tumors using immunoimaging agents comprising nanoclusters incorporating monoclonal antibodies that selectively bind to the cell membrane of tumor cells, and conjugated payloads comprising an encapsulated near-infrared (NIR) fluorescing crystal. The encapsulated fluorescing crystal compound provides excellent non-radiometric imaging of the tumor, and the non-antigenic metal coating encapsulating the fluorescing crystal particles provides a non-destructive necrotic killing of the tumor cells by low-level radiometric amplification and heating of the tumor cell membrane. Thus the very same nanoclusters used during imaging also serve to kill the tumor cells by necrosis, damaging the cell membrane by overheating as a result of secondary irradiation (not by harmful radiometric-induced apoptosis). Also included is a radiometric treatment platform for that better focuses the marked tumor by articulating the patient (180 degrees along one axis, 90 degrees along another), thereby minimizing incident radiation and destroying the tumor without exposing healthy tissue.08-28-2008
20130039859PASSIVATED NANOPARTICLES - Passivated semiconductor nanoparticles and methods for the fabrication and use of passivated semiconductor nanoparticles is provided herein.02-14-2013
20130039860FLUORESCENT IMAGING WITH SUBSTITUTED CYANINE DYES - Compounds and methods are disclosed that are useful for noninvasive imaging in the near-infrared spectral range. The cyanine compounds of Formula I are presented:02-14-2013
20130039861Dye Conjugated Peptides for Fluorescent Imaging - The present application discloses compositions and methods of use of dye conjugated peptides for fluorescent detection, diagnosis and/or imaging. In preferred embodiments, the compositions comprise a DNL complex comprising an anti-hapten antibody or antigen-binding fragment thereof conjugated to an AD moiety and a DDD moiety conjugated to an antibody or antigen-binding fragment thereof that binds to the target antigen, wherein two copies of the DDD moiety form a dimer that binds to the AD moiety to form the DNL complex. More preferably, the compositions comprise a targetable construct comprising at least one hapten and a fluorescent probe. Binding of the DNL complex to the target antigen and of the hapten on the targetable construct to the DNL complex results in fluorescent labeling of the target antigen. Most preferably, fluorescent imaging is of use in intraoperative, intraperitoneal, laparoscopic, endoscopic or intravascular procedures for detection of diseased tissues.02-14-2013
20080206149METHOD, DYE AND MEDICAMENT FOR STAINING THE INTERNAL LIMITING MEMBRANE, EPIRETINAL MEMBRANE, THE VITREOUS AND/OR THE CAPSULE OF AN EYE - The present invention concerns a method of staining the internal limiting membrane, the vitreous and/or the lens capsule of the eye as well as dyes and medicaments suitable for this method. Such dyes, medicaments and methods are needed in ophthalmic surgery, in particular in macular and/or cataract surgery and/or vitrectomy.08-28-2008
20130136698INTEGRATED PHOTOACTIVE AGENTS AND USES THEREOF - The present invention discloses a number of photoactive compounds designed to bind and inhibit serine proteases. Compounds disclosed herein may be utilized in a number of appropriate medical diagnostic and/or therapeutic procedures such as the monitoring of hemostasis, imaging and/or treatment of vulnerable plaques, and/or tumor imaging and/or treatment.05-30-2013
20090155182OPTICAL IN VIVO IMAGING CONTRAST AGENTS AND METHODS OF USE - Provided is an optical in vivo contrast agent comprising a fluorescent polymeric microsphere, wherein the microsphere is impregnated with a dye having an excitation and emission spectrum compatible with in vivo imaging, and wherein the microsphere is coated with a block copolymer.06-18-2009
20100143261COMPOSITION FOR THE DIAGNOSIS, PREVENTION OR TREATMENT OF DISEASES RELATED TO CELLS EXPRESSING IL-8 OR GRO-ALPHA, COMPRISING UCB-MSCS - Provided is a gene therapy composition for transferring one of a therapeutical gene, a maker gene, or a mixture thereof to a cell that expresses interleukin-8(IL-8) or GRO-α and induces tropism of mesenchymal stem cells isolated from umbilical cord blood and/or the mesenchymal stem cells expanded from said mesenchymal stem cells (UCB-MSCs), wherein the cell-treating composition includes UCB-MSCs. Provided is a composition for treating disease related to a cell expressing IL-8 or GRO-α, that is, a brain tumor in gene therapy, by using UCB-MSCs. Provided is a composition or kit for diagnosing brain tumors, preventing brain tumors, treating brain tumors, or monitoring brain tumor treatment progression by using UCB-MSCs.06-10-2010
20130052137PARA AMINO BENZOIC ACID BASED NANOTUBES - The invention relates to nanotubes and processes for making them and intermediates of a drug moiety or its derivative/s as a structural moiety with side chain/s capable of promoting self aggregation. The side chain/s are mono or a multiple of alkyl chain/s that are substituted or unsubstituted capable of creating self aggregating assemblies. A p-amino benzoic acid (PABA) moiety or derivative as a structural moiety of 4-alkylamido-N-pyridin-2yl-benzamide with a lauric or stearic side chain. 4-alkylamido-N-pyridin-2yl-benzamide and 4-Amino-N-pyridine-2 yl-benzamide, N-(Pyridine-2-yl)-4-dodecanamido-benzamide and N-(Pyridin-2-yl)-4-stearamidobenzamide are intermediates useful for in vivo Conjugation of an active ingredient, illustrated by Rhodamine B. With Rhodamine B as an active ingredient, nano-tubes prepared with lauric side chain, which show red fluorescence and is useful for in vivo tracking.02-28-2013
20130052138METHODS AND COMPOSITIONS FOR DIAGNOSTIC AND THERAPEUTIC TARGETING OF COX-2 - The presently disclosed subject matter provides compositions that selectively bind cyclooxygenase-2 and comprise a therapeutic and/or diagnostic moiety. Also provided are methods for using the disclosed compositions for diagnosing (i.e., by imaging) a target cell and/or treating a disorder associated with a cyclooxygenase-2 biological activity.02-28-2013
20090214434METHOD OF DETECTING AND TREATING ALLOGENIC CELLS RESPONSIBLE FOR ENDOMETRIOSIS - There are presently provided methods for identifying an ectopic allogenic cell in a mammalian host, the methods comprising obtaining a first internal soft tissue image, administering an effective amount of iodine to potentiate the host's immune response to aberrant ectopic tissue, obtaining one or more subsequent internal soft tissue images after said administration and comparing the first internal soft tissue image and the one or more subsequent internal images to identify the ectopic allogenic cell. The methods can also be used for determining or improving the efficiency of treatment of pathology disease or disorder caused by the presence of allogenic commensal or commensal-like cells. Furthermore, the methods can be used to diagnose, and also treat, endometriosis.08-27-2009
20100129293Near Infrared Imaging Agent - This invention relates to an in-vivo diagnostic method based on near infrared radiation (NIR radiation) that uses water-soluble dyes and their biomolecule adducts, each having specific photophysical and pharmaco-chemical properties, as a contrast medium for fluorescence and transillumination diagnostics in the NIR range, to new dyes and pharmaceuticals containing such dyes.05-27-2010
20090004115IN VIVO CELL TRAFFICKING - Provided herein are methods of monitoring inflammatory cell migration in a mammal. The methods include the steps of: providing a donor mammalian subject; introducing an inflammatory agent into the donor mammal to create a granuloma; isolating granuloma-derived nucleated cells from the granuloma of the donor mammalian subject; labeling the granuloma-derived nucleated cells with an optical agent; providing a recipient mammalian subject with inflamed tissue; introducing the granuloma-derived nucleated cells into a recipient mammalian subject at a site remote from site where the inflammatory agent was introduced; and imaging the recipient mammalian subject using an optical system. The methods may also include analysing the distribution of the labeled granuloma-derived cells in the recipient mammal.01-01-2009
20090304597Use of an Active Biological Substance in Abnormal Cellular and Viral Membrane Physiologies - An active biological substance is disclosed for use in abnormal cellular and viral membrane physiologies in human and mammal organisms. The active substance has diagnostic and/or therapeutic properties and contains or consists of at least one component selected from the group of substances including: histones, covalently modified histones, histone-like polypeptides, biologically active histone sequences and histone-like polypeptides as agents for stopping the supply to solid tumours over their blood vessels, for killing cells infected by virus and for killing tumour cells with disturbed lipid asymmetry.12-10-2009
20100068150Selective Caspase Inhibitors - Described here are novel, highly selective inhibitors and activity based probes (ABPs) for caspases 3, 7, 8, and 9 and legumain. The compounds selectively inhibit only certain caspases. A positional scanning combinatorial library (PSCL) approach was used to screen pools of peptide acyloxymethyl ketones (AOMKs) containing both natural and non-natural amino acids for activity against a number of purified recombinant caspases. These screens were used to identify structural elements at multiple positions on the peptide scaffold that could be modulated to control inhibitor specificity towards target caspases. Further disclosed are individual optimized covalent inhibitors that could also be equipped with various tags for use as activity based probes, as well as labeled substrates.03-18-2010
20090098057SILICA-CORED CARRIER PARTICLE - A nanoparticulate imaging probe with an oxide core, a biocompatible polymeric shell covalently attached to the oxide core, a dye, and a cleavable spacer that covalently binds the dye to the probe. When the spacer is cleaved, the dye is liberated from the probe. The emissions of the dye are quenched when the dye is bound to the probe and not quenched when the dye is liberated from the probe. The spacer can be, for example, a peptide. The oxide core can be, for example, a silicon oxide core.04-16-2009
20100272651METHOD FOR ASSESSING POTENTIAL FOR TUMOR DEVELOPMENT AND METASTASIS - The present invention generally provides methods for assessing the potential of tumor formation and/or metastasis using a combination (e.g., a ratio) of the number of circulating tumor cells and the number of circulating cells exhibiting autofluorescence within a selected wavelength region (e.g., red autofluorescence). In one aspect, it is directed to a method for providing likelihood of occurrence of a primary and/or a metastatic cancerous tumor in an animal, which comprises inoculating the animal with a plurality of cancer cells, determining a ratio of a number of cancer cells relative to a number of circulating indicator cells (e.g., immature leukocytes) that exhibit autofluorescence in the inoculated animal's blood and correlating the ratio to a likelihood that the animal will develop at least one primary and/or metastatic cancerous tumor, e.g., by way of assigning a probability for tumor development and/or metastasis based on the measured ratio. The method can also be utilized in human studies using, e.g., contrast agents to identify the circulating tumor cells.10-28-2010
20090041670Near Infrared Fluorescent Contrast Agent And Method For Fluorescence Imaging - A near infrared fluorescent contrast agent which is excellent in permeability in a living tissue and enables specific imaging of tumor and/or blood vessel, comprising a compound represented by formula (I) or a pharmaceutically acceptable salt thereof, wherein R02-12-2009
20090041669Light-Emitting Biomarker - The invention concerns novel 1,2-dioxetane derivatives of general formula (I) as defined in the description, capable of emitting a detectable luminescent signal, their use in a method for detecting and/or quantizing a physical, chemical or biological, in particular enzymatic, phenomenon, as well as a kit for implementing said method.02-12-2009
20130058871METHOD AND SYSTEM FOR MAPPING SYNAPTIC CONNECTIVITY USING LIGHT MICROSCOPY - A mammalian Green Fluorescent Protein (GFP) Reconstruction Across Synaptic Partners (mGRASP) method and system is provided by optimizing synaptic transmelectron microscopicbrane carriers for mammalian synapses. The method and system in one form integrates molecular and cellular approaches with a novel computational strategy to reliably reconstruct neurons in 3D. The method and system allows mGRASP to be applied to both long-range and local microcircuits, analysis of synaptic distribution at the level of single neurons and dendritic compartments within neural cells.03-07-2013
20130058872Bioluminescent Endoscopy Methods and Compounds - Bioluminescent endoscopy methods in which bioluminescent generating system components are combined ex vivo immediately prior to injection or infusion into a tissue area of interest to enable bioluminescent viewing of the tissue. The bioluminescent generating system components are combined by simultaneous injection into a Y tube or other in-line mixing chamber receiving fluid inputs from two or more fluid conduits and providing a fluid output to at least one fluid conduit. The mixed components which are the output of such multi lumen mixing system is injected into a hollow viscus organ or otherwise applied to organs and/or tissues of the body.03-07-2013
20110038803FLUORESCENT PROBE - A fluorescent probe which specifically and efficiently traps nitrogen monoxide, zinc ion etc. to emit fluorescence is provided.02-17-2011
20090269283METHOD AND PRODUCT FOR LOCATING AN INTERNAL BLEEDING SITE - A method is provided for localizing an internal bleeding site whereby a protein or other factor involved in the clotting process is complexed to an imaging agent and injected into a patient believed to be at risk of internal bleeding. A clot in the patient will naturally accumulate a certain concentration of the injected complex, and within a short period of time the concentration becomes sufficient to be detected by an imaging apparatus. The imaging contrast agent may, for example, be an MRI contrast agent, a CT contrast agent, a PET agent, or a fluorescent substance.10-29-2009
20130064776LABELLED SILICA-BASED NANOMATERIAL WITH ENHANCED PROPERTIES AND USES THEREOF - The present invention relates to labelled silica-based nanoparticles with enhanced properties, to process for preparing them and to uses thereof.03-14-2013
20130164220COLLAGEN MIMETIC PEPTIDES FOR TARGETING COLLAGEN STRANDS FOR IN VITRO AND IN VIVO IMAGING AND THERAPEUTIC USE - The present invention provides both a caged collagen mimetic peptide (CCMP) having the formula: L-S-Z06-27-2013
20090238766BIOLUMINESCENT CONSTRUCT - The invention provides a construct comprising an amino acid sequence attached to a luciferin substrate, wherein the amino acid sequence is not a substrate for either luciferase or caspase-3/7 to render the substrate inactive in the presence of luciferase. The construct is useful, for example, as a negative control for in vitro apoptosis assays and the bioluminescent imaging of drug-induced apoptosis in vivo. The invention also provides methods for screening for novel modulators of an apoptosis-related disease.09-24-2009
20090238765Fluorescent Contrast Agent - The invention relates to contrast agents for imaging of diseases associated with inflammations. More specifically the invention provides optical imaging contrast agents for imaging of activated leukocytes and methods for imaging of such. The contrast agent changes its fluorescent properties upon reaction with oxidants produced by the activated leukocytes.09-24-2009
20090232741Optical Imaging - This invention relates to a method for imaging of wet age-related macular degeneration (AMD) using a contrast agent comprising a vector attached to an optical imaging reporter, wherein the vector has affinity for receptors associated with angiogenesis. The invention further provides such methods for monitoring the effect of treatment of AMD.09-17-2009
20090285761Renal Function Analysis Method and Apparatus - A method for measuring a glomerular filtration rate in a mammalian kidney comprises a source of reporter and marker fluorescent molecules. The fluorescent molecules are introduced into the blood stream of a mammalian subject. Over a period of time, a measurement of the intensities of the reporter and marker fluorescent molecules is taken. A ratio is calculated to determine the health of the subject's kidney. This method measures volume of plasma distribution based on a fluorescence of a marker molecule relative to a fluorescence of a reporter molecule.11-19-2009
20120114563OPTICAL IMAGING AGENTS - The present invention relates to a method of in vivo optical imaging, of the margins around tumours, which comprises an optical imaging contrast agent. The optical imaging agents comprise conjugates of near-infrared dyes with synthetic polyethylene glycol (PEG) polymers having a molecular weight in the range 15-45 kDa. Also disclosed are optical imaging contrast agents, pharmaceutical compositions and kits.05-10-2012
20090010851Fluorescent Pyrazine Derivatives and Methods of Using the Same in Assessing Renal Function - The present invention relates to pyrazine derivatives such as those represented by Formulas I and II. X01-08-2009
20110020240Use of bacterial beta-lactamase for in vitro diagnostics and in vivo imaging, diagnostics and therapeutics - Provided herein are imaging methods for detecting, diagnosing and imaging pathogenic bacteria or a pathophysiological condition associated therewith using fluorogenic substrates for bacterial enzymes. Fluorescent, luminescent or colorimetric signals emitted by substrates or enzyme products in the presence of the bacteria are compared to controls to detect and locate the pathogenic bacteria. Provided is a method for screening therapeutic agents to treat the pathophysiological conditions by measuring a signal emitted from the fluorogenic substrates or products in the presence and absence of the potential therapeutic agent. In addition, a diagnostic method for detecting a mycobacterial infection in a subject by contacting biological samples with a fluorogenic substrate and imaging for signals emitted from a mycobacterial beta-lactamase product. Provided are fluorogenic substrates CC1, CC2, CHPQ, CR2, CNIR1, CNIR2, CNIR3, CNIR4, CNIR5, CNIR5-QSY22, CNIR7, CNIR9, CNIR10, CNIR-TAT, CDC-1, CDC-2, CDC-3, CDC-4, CDC-5, XHX2-81, XHX2-91, XHX3-26, or XHX3-32 or a derivative thereof.01-27-2011
20120237451NOVEL MOLECULAR BEACONS - The invention provides novel compositions and methods for the detection of a target molecule. Specifically, the invention provides a bimolecular beacon composition comprising two nucleic acid molecules, and methods thereof. One of the nucleic acid molecule is operably linked to a reporter detectable label and the other nucleic acid molecule is operably linked to a reference detectable label and a quencher. In some embodiments, at least one of the nucleic acid molecules comprises a single stranded overhang.09-20-2012
20130164221USE OF BACTERIAL BETA-LACTAMASE FOR IN VITRO DIAGNOSTICS AND IN VIVO IMAGING, DIAGNOSTICS AND THERAPEUTICS - Provided herein are methods for detecting, quantifying, differentiating, diagnosing and imaging pathogenic bacteria or condition associated therewith using substrates for bacterial enzymes. Fluorescent, luminescent or colorimetric signals emitted by substrates or enzyme products in the presence of the bacteria are compared to controls to detect and locate the pathogenic bacteria. Provided is a method for screening therapeutic agents to treat the pathophysiological conditions by measuring a signal emitted from the substrates or products in the presence and absence of the potential therapeutic agent and a diagnostic method for detecting a mycobacterial infection in a subject by contacting biological samples with a substrate and imaging for signals emitted from a mycobacterial beta-lactamase product. Also provided are fluorogenic substrates or substrates comprising a colored dye or a chemical reagent effective to induce a color or pH change.06-27-2013
20110027190COMPOSITION OF A FIRST NON-LABELED MONOCLONAL ANTIBODY BINDING TO A TUMOR ANTIGEN AND A NON-CROSS REACTIVE SECOND MONOCLONAL ANTIBODY LABELED WITH A NIR FLUORESCENCE LABEL - This invention relates to a composition of a non-labeled monoclonal antibody binding to a tumor antigen and a second monoclonal antibody labeled with a NIR fluorescence label, binding to the same tumor antigen, wherein the first and second antibody exhibit no cross reactivity. The composition can be used for the treatment of patients suffering of solid tumors which are associated with an overexpression of such a tumor antigen. The invention further relates to a the co-administration of said first and second antibody as wells as to a method of acquiring a NIR fluorescence images of such tumors or the patients suffering from such tumors during the treatment of said patient with such composition.02-03-2011
20110280810SURGICAL OPTICAL SYSTEMS FOR DETECTING BRAIN TUMORS - A method of detecting a brain tumor includes administering indocyanine green to a living body; exposing brain tissue in the living body; irradiating the exposed brain tissue with excitation light of indocyanine green; obtaining an image based on fluorescence of the excited indocyanine green in the brain tissue, wherein the image is obtained using an endomicroscope; and identifying portions of the brain tissue corresponding to the brain tumor based on the image.11-17-2011
20110280811METHOD OF MEASURING PROPULSION IN LYMPHATIC STRUCTURES - Novel methods and imaging agents for functional imaging of lymph structures are disclosed herein. Embodiments of the methods utilize highly sensitive optical imaging and fluorescent spectroscopy techniques to track or monitor packets of organic dye flowing in one or more lymphatic structures. The packets of organic dye may be tracked to provide quantitative information regarding lymph propulsion and function. In particular, lymph flow velocity and pulse frequency may be determined using the disclosed methods.11-17-2011
20100266506Flourescent Dendrimer Compounds and Use of Such Compounds in Multi-Photon Devices or Processes - Fluorescent chemical compound composed of an n-generation dendrimer, n being a non-zero integer, exhibiting: -at least one central nucleus (N) with a valency of m, selected from the group consisting of -at least one first, non-chromophoric unit (X) with a valency of m′, and -at least one second unit (Y) which exhibits two-photon absorption properties, with a valency of m″.10-21-2010
20080260647Method for Fluorescence Tomographic Imaging - There is provided a method for determining the concentration of a fluorophore in a medium using moments of order k of the fluorescence signal. The method allows higher fidelity 3-dimensional reconstructions of the fluorophore in the medium. The method can be applied in imaging of fluorophores in biological tissues.10-23-2008
20090098058METHOD OF INJECTING LIQUID AGENTS AT ACUPUNCTURE POINTS TO ARRIVE INTERNAL ORGANS AND METHOD OF VISUALIZING ARRIVAL OF LIQUID AGENTS - Provided are a method of injecting a visualizing material into a point in the vicinity of the Jung-Wan and a method of visualizing arrival of liquid agent in order to verify that the visualizing material injected arrives at internal organs. A point having the lowest electric resistance is found in the vicinity of Jung-Wan of the subject by using an electro acupuncture point detector. The visualizing material is injected into the point by means of an injecting instrument and then verified at least one point of the pancreas and the threadlike structures on top of the surface of the pancreas. The visualizing material is an alcian blue solution or a nanoparticle-containing solution labeled with fluorescent organic material.04-16-2009
20120251459SPECIFIC INHIBITORS AND ACTIVE SITE PROBES FOR LEGUMAIN - Compounds which specifically inhibit legumain, also known as asparaginyl endopeptidase are provided. The compounds have an epoxide or N-Michael acceptor warhead, and have an asparagine side chain attached to a nitrogen atom in the backbone adjacent the warhead. The compounds also preferably comprise a proline residue adjacent the asparagine, and the compound may also contain a third residue and/or a label for cellular or in vivo imaging of active legumain.10-04-2012
20110286932OPTICAL METHOD FOR THE DETECTION OF ALZHEIMER'S DISEASE - The present subject matter relates to a non-invasive optical imaging method for monitoring early pathological events specific to Alzheimer's disease (AD), such as the development, amount and location of amyloid plaques. The ability to monitor such events provides a basis for, among other things, AD diagnosis, prognosis and assessment of potential therapies. In addition, the present subject matter introduces novel methods for treating AD and retinal ailments associated with AD. Aβ-plaque detection in living brains is extremely limited, especially at high resolution; therefore the present invention is based on studies focusing on the eyes as an alternative to brain-derived tissue that can be imaged directly, repetitively and non-invasively.11-24-2011
20110286934MEMBRANE TRANSDUCTION PEPTIDES, POLYNUCLEOTIDES, AND METHODS - Isolated polypeptides, nucleic acids, and methods relating to cellular internalization of materials are described herein. Generally, the isolated polypeptides include a membrane transduction domain of human tissue factor pathway inhibitor-2 (TFPI-2). In some cases, the isolated polypeptide can be a fusion peptide that includes a membrane transduction domain of human TFPI-2 and a heterologous peptide domain. The nucleic acids include nucleic acids that encode the isolated polypeptides described herein. The methods generally include providing a composition that includes a membrane transduction domain of human TFPI-2 coupled to a material, and contacting the composition with a cell under conditions effective to permit the cell to internalize the composition.11-24-2011
20110286933MONOFUNCTIONAL CARBOCYANINE DYES FOR IN VIVO AND IN VITRO IMAGING - The present invention provides symmetric carbocyanine dyes and dye precursors useful for fluorescence microscopy, and methods of making and using same.11-24-2011
20090274629Sanitizing Composition and Method of Preparation - The invention provides a sanitizing composition in the form of a viscous liquid or gel suitable for use as a handwash composition comprising alcohol, water and a thickener wherein the viscous liquid or gel has particles suspended therein, wherein said particles provide the composition with a granular texture and are capable of being worn away when rubbed. The particles may deliver one or more agents to the skin e.g. antimicrobial, antibacterial or antiviral agents, emollients and/or moisturizers, fragrances, colourings or UV markers.11-05-2009
20110293529FLUORESCENT NIRF ACTIVATABLE PROBES FOR DISEASE DETECTION - Fluorescent activatable probes for imaging biological processes and disease detection in vitro and in vivo. There is also described a method for detecting the presence of an enzyme. A sample is contacted with a nanoparticle including a monomer, at least one cleavable spacer comprising at least one fluorescence activation site, and at least two dyes of at least two types. The cleavable spacer is attached at one end to the nanoparticle. The at least two types comprise an energy donor type and an energy acceptor type. At least one dye of one type is embedded in the nanoparticle and the cleavable spacer has at least one dye of the other type attached. The at least two dyes comprise at least one matched pair capable of fluorescence resonance energy transfer. Fluorescence is detected by exposing the sample to a light source, and detecting emitted light with a detector.12-01-2011
20100021390Fluorescent Analogs Of The Islet Amyloid Polypeptide - The present invention relates to methods and compositions for the investigation of amyloid formation. In preferred embodiments, amyloid formation associated with type II diabetes is monitored by fluorescence spectroscopic measurements of the activity of p-cyano-phenylalanine-substituted islet amyloid polypeptide, and derivatives thereof, under an amyloid-forming condition. In some embodiments, the amyloid-forming condition is associated with a diseased, or putatively diseased, cell or tissue. In some embodiments, the invention provides a method of evaluating the severity of the amyloid-forming condition, and changes therein induced by agents that inhibit, or potentially inhibit, amyloid formation.01-28-2010
20110300076METHODS FOR PREPARATION OF ZnTe NANOCRYSTALS - Nanocrystals having a ZnTe core and methods for making and using them to construct core-shell nanocrystals are described. These core-shell nanocrystals are highly stable and provide quantum yields and stability suitable for applications such as flow cytometry, cellular imaging, and protein blotting, medical imaging, and other applications where cadmium toxicity is an issue.12-08-2011
20100034749Use of a Cationic Collodal Preparation for the Diagnosis and Treatment of Ocular Diseases - The present invention relates to cationic colloidal preparations and their use for the diagnosis and/or treatment of ocular diseases.02-11-2010
20120189550ORALLY ADMINISTERED BACTERIA AS VEHICLES FOR SYSTEMATIC DELIVERY OF AGENTS - The current invention relates to the use of a bacterial species in the preparation of a composition adapted for oral administration for the delivery of an agent to a site in the body. The site in the body may be an organ or a tumour site. The bacterial species is a food grade, non-pathogenic, gram-positive bacteria capable of anaerobic growth.07-26-2012
20110268660METHOD FOR DETECTING DYSPLASIA - The present invention provides a method of imaging useful in the determination of sites of dysplasia in patients suffering from Barrett's oesophagus. The method comprises the use of an optical imaging agent comprising a vector which targets the extracellular domain of EGFR, the vector also being selective for EGFR over Her2. The vector is labelled with an optical reporter suitable for in vivo imaging using light in the green to near-infrared wavelength 500-1200 nm. Also provided are novel optical imaging agents suitable for use in the method.11-03-2011
20090148386ENZYME SUBSTRATE COMPRISING A FUNCTIONAL DYE AND ASSOCIATED TECHNOLOGY AND METHODS - Enzyme substrates and associated technology of the present invention are provided. An enzyme substrate of the invention may comprise a biologically functional fluorescent dye and an enzyme-specific substrate moiety attached in such a way that the functionality of the functional dye is diminished. An enzymatic reaction may cleave at least a portion of the substrate moiety from the enzyme substrate to provide a more functional product dye. This product dye may be nonfluorescent or weakly fluorescent, in general, and relatively fluorescent, in a particular condition, such as when bound to a partner biological molecule or an assembly of partner biological molecules. An enzyme substrate of the present invention may thus be useful in fluorescence detection, and/or in any of a variety of useful applications, such as the detection of enzymatic activity in a cell-free system or in a living cell, the screening of drugs, or the diagnosis of disease.06-11-2009
20100202976SUBSTANCE-ENCAPSULATING CARBON NANOHORN AGGREGATE AND PROCESS FOR PRODUCING THE SAME - A substance-encapsulating carbon nanohorn aggregate which has improved chemical stability by isolating the encapsulated substance from outside and which is useful as a targeting material which can be led from the outside of the body or as a contrast medium by holding the encapsulated substance in an aggregated form, and a process for producing the same are provided. The substance-encapsulating carbon nanohorn aggregate is characterized in that the encapsulated substance is aggregated in a central part of the carbon nanohorn aggregate or a neighborhood thereof with being isolated from outside. The process includes aggregating a substance to be encapsulated in a central part or a neighborhood thereof by a heat treatment.08-12-2010
20090142274Intracellular nanosensors and methods for their introduction into cells - The invention provides ion-selective sensors capable of selectively measuring ions, e.g., Na06-04-2009
20080292555Quantitative Two-Photon Flow Cytometry - A method and apparatus of multi-dye analysis of particles using flow cytometer. The method includes dying particles to be detected using two or more dyes; urging the particles through a capillary in a non-uniform flow; exciting a first of the particles within the capillary using a multiphoton excitation laser beam causing the two or more dyes each to fluoresce thereby producing a first output signal and a second output signal respectively; and detecting the first output signal and the second output signal. A second of the particles within the capillary being excited using the multiphoton excitation laser beam causing the two or more dyes each to fluoresce thereby producing a third output signal and a forth output signal respectively. The method finally includes comparing a ratio of the first output signal and the second output signal to a ratio of the third output signal and the forth output signal to detect a desired change in the particles.11-27-2008
20100278745COMPOUNDS FOR FLUORESCENCE IMAGING - Methods and compositions involving enzyme-activatable fluorophore polymer imaging agents for photodetection of specific tissues and/or human diseases and disorders are provided. In certain embodiments, the imaging agent comprises a hydrophilic polymer backbone (e.g., poly(L)lysine), a hydrophobic fluorophore, and a hydrophilic solubilizing agent. The solubilizing agent may comprise a quarternary ammonium group (e.g., a 1-methylnicotinic group) to enhance self-quenching of the fluorophore. Various methods for the generation and purification of imaging agents are also provided, including methods involving solid phase probe extraction or ion exchange purification.11-04-2010
20100119457COMPOSITION OF LABELED AND NON-LABELED MONOCLONAL ANTIBODIES - This invention relates to a composition of labeled and non-labeled monoclonal antibodies directed to a human transmembrane protein for the simultaneous treatment and diagnosis of diseases which are associated with an overexpression of such a protein especially of cancer. The invention further relates to a method of first administering said composition, determine the change of labeled antibody concentration and afterwards administering the non-labeled monoclonal antibodies only such that the minimum required concentration of such non-labeled antibody for a favorable therapeutical effect is achieved and maintained in the treatment, while unfavorable side effects are minimized due to the lower systemic antibody concentration.05-13-2010
20100092393TUNABLE HYDROGEL MICROPARTICLES - Techniques are provided to produce and use non-spherical colloidal particles with independently tuned size, shape, flexibility, and chemical properties. A pre-polymer mixture for forming hydrogel particles includes a percentage of PEGDA selected to impart a target stiffness to the particles and includes, a percentage of acrylic acid selected to impart an independent target chemical function to the particles. The mixture also includes a percentage of photo-initiator to polymerize PEGDA upon exposure to a light source to impart an independently selected target size or shape or both to the particles.04-15-2010
20100080758OPTICAL FLUORESCENT IMAGING - Compounds and methods are disclosed that are useful for noninvasive imaging in the near-infrared (NIR) spectral range. The NIR is highly sensitive for tumor detection and tracking. The application discloses targeting a tumor-enriched cell surface receptor with a ligand-conjugated fluorescent probe, which specifically allows detection of the tumor relative to the negligible animal autofluorescence.04-01-2010
20120107244MONOMERIC VARIANTS OF THE TETRAMERIC eqFP611 - Monomeric eqFP611 variants exhibit red fluorescent properties and DNA encoding monomeric eqFP611 variants.05-03-2012
20090263328FLUORESCENCE OBSERVATION APPARATUS AND FLUOROSCOPY METHOD - A site of interest to be observed is clearly observed in an image during fluoroscopy of a small laboratory animal, even when the fluorescence is extremely low. The invention provides a fluorescence observation apparatus including a light source that emits excitation light; an optical system that irradiates an image-acquisition site on a small laboratory animal with the excitation light from the light source; a light-blocking unit that blocks light in a prescribed region of the small laboratory animal or in an image of the prescribed region; an image-acquisition unit that acquires a fluorescence image of the small laboratory animal; and a control unit configured to identify a high-fluorescence region having a prescribed fluorescence level or above in the fluorescence image of the small laboratory animal acquired by the image-acquisition unit and to control the light-blocking unit so as to block light at the identified high-fluorescence region.10-22-2009
20110200532Fluorescent emulsion of indocyanine green - The present invention relates to a formulation of indocyanine green in the form of a nanoemulsion, comprising a continuous aqueous phase and at least one dispersed oily phase, in which the oily phase comprises indocyanine green, at least one amphiphilic lipid and at least one solubilising lipid.08-18-2011
20090169482SILICA-CORED CARRIER PARTICLE - A nanoparticulate imaging probe with an oxide core, a biocompatible polymeric shell covalently attached to the oxide core, a dye, and a cleavable spacer that covalently binds the dye to the probe. When the spacer is cleaved, the dye is liberated from the probe. The emissions of the dye are quenched when the dye is bound to the probe and not quenched when the dye is liberated from the probe. The spacer can be, for example, a peptide. The oxide core can be, for example, a silicon oxide core.07-02-2009
20090202442Enerceutical activation of the alternative cellular energy (ACE) pathway in therapy of diseases - Alternative cellular energy pigments (ACE-pigments) provide a source of cellular energy other than that provided through the oxidative metabolism of foods, or in the case of plants and certain bacteria, through the process of photosynthesis. In some patients, ACE pigments exist in a form that can be further energized or activated using ultraviolet (UV) light, especially if the reaction is initially triggered by the presence of suitable dyes, such as neutral red. A method is described to further enhance the activation of the ACE pathway in humans and animals deprived of ACE. The method comprises using natural or man-made sources of ACE products (enerceuticals), with or without the inclusion of a suitable dye, such as neutral red; and applying the material(s) to the skin, either directly or separated by an impermeable barrier; and illuminating the enerceutical with a UV light source. The process of activating the ACE pathway is evidenced by UV inducible fluorescence seen within areas of the patients' skin and/or mucus membranes. This fluorescence fades as the ACE pathway becomes fully activated. Activating the ACE pathway can have therapeutic benefits in various infectious and non-infectious diseases. Cited examples include autism, Morgellons disease, herpes virus infections and cellulite.08-13-2009
20120294807FLUORESCENT COMPOUNDS - Compounds used as labels with properties comparable to known fluorescent compounds. The compounds can be conjugated to proteins and nucleic acids for biological imaging and analysis. Synthesis of the compounds, formation and use of the conjugated compounds, and specific non-limiting examples of each are provided.11-22-2012
20110206616RECOMBINANT DERIVATIVES OF BOTULINUM NEUROTOXINS ENGINEERED FOR TRAFFICKING STUDIES AND NEURONAL DELIVERY - This invention relates to isolated 08-25-2011
20120294808Fluorescent Analogs of Neurotransmitters, Compositions Containing the Same and Methods of Using the Same - A method of imaging using selective fluorescent emitters and compositions for imaging are described. The method can include contacting a specimen with a composition comprising at least one selective fluorescent emitter of Formulas I through IX and irradiating the specimen with an excitation wavelength. The fluorescence emitted by the selective fluorescent emitter can be detected to generate an image. Formulas I through IX are:11-22-2012
20100278747CARRIER - The invention relates to a carrier for delivering agents to the posterior region of the eye, the carrier comprising a Vitamin E derivative, especially tocopherol. The carrier may also comprise a cell death marker, such as an annexin.11-04-2010
20100278746Method for Measuring Neurotransmitters in Vivo - A method is provided for in vivo detection of a biochemical substance in an animal by culturing neurofluocytes that stably express a receptor of the biochemical substances by transfecting cells with cDNA of the receptor and a tag that will emit a detectable energy in the presence of the biochemical substance, implanting the neurofluocyte into the animal's brain; and detecting the energy emission of the tag. In a first embodiment, the biochemical substance is a neurotransmitter, the tag is a fluophore, and the step of detecting includes forming an opening in the animal's skull and optically detecting fluorescent emissions using a two-photon laser scanning microscope. Multiple biochemical substances can be simultaneously detected by culturing neurofluocytes that express different receptors and have different fluophor tags that produce fluorescent signals at distinguishable wavelengths.11-04-2010
20110268662FUNCTIONALIZED NANOCERIA COMPOSITION FOR OPHTHALMIC TREATMENT - The invention provides a composition comprising a plurality of nanoceria particles, a sufficient amount of at least one inhibitor of human carbonic anhydrase II associated with said plurality of nanoceria particles, and a pharmaceutically acceptable carrier containing said plurality of nanoceria particles with associated inhibitor. One preferred inhibitor of human carbonic anhydrase II comprises 4-carboxybenzene sulfonamide. The disclosed composition is useful in treatment of glaucoma.11-03-2011
20110268661FLUORESCENT FUSION POLYPEPTIDES AND METHODS OF USE - Embodiments of the present invention provide for the facile generation of a stable recombinant fusion polypeptides with intrinsic fluorescent properties. The recombinant antibodies may be suitable for qualitative and/or quantitative immunofluorescence analysis. Generally, the fluorescent polypeptides include a fluorescent domain comprising a C-terminus and an N-terminus; a first antibody domain covalently linked to the C-terminus; and a second antibody domain covalently linked to the N-terminus.11-03-2011
20080213188NOVEL OPHTHALMIC COMPOSITIONS CONTAINING HUMAN RECOMBINANT LYSOZYME AND USE THEREOF FOR TREATING EYE CONDITIONS AND AS CONTACT LENS SOLUTIONS - An ophthalmic solution comprising: a) a human recombinant lysozyme; b) one or more natural lacrophyl substances; c) water; and d) optionally one or more therapeutic substances. The ophthalmic solution is useful to treat dry eye conditions and eye inflammation and also to condition and/or cleanse contact lenses. It is emphasized that this abstract is provided to comply with the rules requiring an abstract which will allow a searcher or other reader quickly to ascertain the subject matter of the technical disclosure. It is submitted with the understanding that it will not be used to interpret or limit the scope or meaning of the appended issued claims.09-04-2008
20090169483FLUORESCENT PHOTOPROBE FOR THE IMAGING OF ENDOTHELIN RECEPTORS - The present invention relates to a endothelin receptor antagonist conjugate of the formula (I) wherein R07-02-2009
20080233050Diagnostic and therapeutic optical agents - Disclosed herein are compounds that may be characterized by some as cyanine and indocyanine dye bioconjugates. Compounds disclosed herein may be utilized (e.g., in the form of a pharmaceutically acceptable composition) in a number of medical procedures, such as in the visualization and detection of tumors.09-25-2008
20080286208Eye treatment - The invention relates to a method of diagnosing the eye and to methods for subsequent treatment following such diagnosis. The method involves diagnosing a deficiency in the anatomy and performance of the upper eyelid recognizing the impact of this deficiency during blinking on problems such as dry eye, contact lens intolerance and ocular discomfort in general. The invention also involves the use of this diagnostic method to provide a treatment modality to alleviate such problems.11-20-2008
20080286207Polycyclo Dyes and Use Thereof - The invention relates to a family of fluorescent compounds that comprise a bridged polycyclo moiety. The compounds can be chemically linked to biomolecules, such as proteins, nucleic acids, and therapeutic small molecules. The compounds can be used for imaging in a variety of medical, biological and diagnostic applications, and are particularly useful for the in vivo imaging of regions of interest within a mammal.11-20-2008
20080305047Chemosensors Based on Quantum Dots and Oxazine Compounds - We identified a mechanism to detect chemical changes with a modified semiconductor nanoparticle (e.g., an oxazine-adsorbed CdSe—ZnS core-shell quantum dot). Our strategy is based on the chemical transformation of chromo-genie ligands adsorbed on the surface of a quantum dot. This activates an energy transfer pathway from the quantum dot to the adsorbed chromogenic ligands, which causes a change (e.g., increase or decrease) in a characteristic of fluorescent emission (e.g., intensity or lifetime). Thus, modified quantum dots acting through this mechanism can efficiently transduce a chemical event or occurrence into a change in optical signal. Our design can be adapted to signal chemical changes by a diversity of target analytes and, thus, it can be used to develop other fluorescent chemosensors based on the unique properties of quantum dots.12-11-2008
20080311047Multimetric Biosensors and Methods of Using Same - Multimeric tryptophan biosensors are disclosed, which comprise tryptophan-binding domains conjugated to donor and fluorescent moieties that permit detection and measurement of Fluorescence Resonance Energy Transfer upon tryptophan binding. Such biosensors are useful for real time monitoring of tryptophan metabolism in living cells.12-18-2008
20080241071Quantum Dot Probes - Novel nanoparticulate compositions of luminescent probes, as well as methods of using such compositions and systems comprising such compositions are provided. One such composition comprises at least one probe comprising a quantum dot, at least one metal nanoparticle, and at least one tether that is attached to the quantum dot and to the at least one metal nanoparticle. One such method comprises providing at least one such probe, introducing the at least one probe into a subject; and detecting luminescence from the at least one probe in the subject. One such system comprises at least one such probe and a detector capable of detecting luminescence from the quantum dot, wherein the detector is positioned in relation to the at least one probe such that luminescence can be detected.10-02-2008
20100143258TUMOR MARGIN IMAGING AGENTS - In one aspect, the present invention provides a functionalized monodisperse polylysine comprising a linear monodisperse polylysine chain comprising constituent lysine monomer residues containing appended C06-10-2010
20100143260COATING SYSTEM - Embodiments of the invention include a system comprising: an Acetoxy curable silicone Binder; and an active agent blended with the silicone binder, effective for one or more of radiopacification, lubricity, elution of a secondary compound such as a drug, echogenic properties, thermal or electrically insulative properties or chemical indicators wherein the silicone binder effectiveness is not substantially changed by the active agent.06-10-2010
20090123382Light emitting microorganisms and cells for diagnosis and therapy of tumors - Provided are diagnostic and pharmaceutical compositions containing a microorganism or a cell containing a DNA molecule encoding a detectable protein or a protein that a detectable signal, such as a luminescent or fluorescent protein. Methods of tumor targeting and tumor imaging using the microorganisms and cells are provided. Also provided are therapeutic methods in which the microorganisms and cells, which can encoded a therapeutic protein, such as a cytotoxic or cytostatic protein, are administered.05-14-2009
20100143259FLUORESCENT MICROSPHERES, THE PREPARATION METHOD AND USES THEREOF - The invention discloses the microspheres comprising the following structure in the composition thereof and the uses as tracers and fluorescent standard calibration products.06-10-2010
20110206618Fluorescent labeling material and flourescent labeling agent - Provided is a fluorescent labeling material, including zinc oxide nanoparticles each surface-modified with an organic compound having an amino group placed at an outer end thereof. Also provided is a fluorescent labeling agent to be used in vivo or in vitro, including the fluorescent labeling material, in which: EDC or the like is bound thereto through the amino group; and a substance capable of selectively binding to a target to be fluorescently labeled, such as an antibody, is linked thereto.08-25-2011
20110206617MODIFIED POLYSACCHARIDES FOR DRUG AND CONTRAST AGENT DELIVERY - According to one embodiment, the disclosure provides a delivery formulation including a chitosan in which the primary amines are partially modified with 4-imidazole acetic acid monohydrochloride and a therapeutic or imaging material. According to another embodiment, the disclosure provides a method for delivering a material to an epithelial or mucosal tissue comprising increasing the permeability of an epithelial or mucosal tissue by applying to said tissue a delivery formulation including a chitosan in which the primary amines are partially modified with 4-imidazole acetic acid monochlorohydride and a therapeutic or imaging material.08-25-2011
20120070382FLUORESCENT CONJUGATED POLYMERS WITH A BODIPY-BASED BACKBONE AND USES THEREOF - The present invention provides various fluorescent conjugated polymers with a BODIPY-based backbone. The invention also provides methods of using the polymers of the invention, such as for imaging and detection of cells, tumors, bacteria and viruses.03-22-2012
20120070381OPHTHALMOLOGIC COMPOSITION HAVING GELATION ABILITY - Disclosed is a material for use in ophthalmologic organ replacement, which is transparent, has controllable physical properties, and can have physical properties suitable for use as an ophthalmic tissue when the hardness of a gel produced from the material or the fluidability of a sol produced from the material at a specific temperature or lower is varied. Specifically disclosed is an ophthalmologic composition capable of forming a gel, which comprises a polyethylene glycol that is represented by formula 1 and has one end modified with a long-chain alkyl group, a polyethylene glycol that is represented by formula 2 and has both ends modified with a long-chain alkyl group, and a solvent.03-22-2012
20120070380Ingestible salt grabber - Disclosed herein include embodiments related to compositions, devices, computer systems, computer-implemented methods, and computer program products associated with an ingestible salt grabber.03-22-2012
20080317674Method and Reagent for Measuring Nitroreductase Enzyme Activity - Disclosed are nitro-substituted squaraine reporter dyes and methods using such dyes for detecting nitroreductase enzyme activity and nitroreductase gene expression in cellular assays. The dyes are of the structure:12-25-2008
20110223110STABLE INDIUM-CONTAINING SEMICONDUCTOR NANOCRYSTALS - Nanocrystals having an indium-based core and methods for making them and using them to construct core-shell nanocrystals are described. These core-shell nanocrystals are highly stable and provide higher quantum yields than known nanocrystals of similar composition, and they provide special advantages for certain applications because of their small size.09-15-2011
20080299044Saccharide Fluorescent Substrates, Preparation Method and Uses Thereof - The invention concerns saccharide type fluorescent enzymatic substrates comprising on the same saccharide unit a fluorophor F1 and an inhibitor of the fluorescence of F1, and their use for preparing a diagnostic reagent for in vivo functional imaging, as well as a diagnostic reagent containing at least such an enzymatic substrate.12-04-2008
20110229416AMPHIPHILIC MACROMOLECULES FOR SOLUBILIZING NANOCRYSTALS - Certain embodiments of the invention provide amphiphilic macromolecules and nanocrystals encapsulated by amphiphilic macromolecules. Additionally, certain embodiments of the invention also provide nanocrystals that are water-solubilzed using functionalized AMs capable of coordinating to the nanocrystal surface.09-22-2011
20110229415SEMI-SYNTHETIC ANTIBODIES AS RECOGNITION ELEMENTS - The presently-disclosed subject matter is directed to biosensors for detecting molecules of interest, and systems and methods for using same. The biosensors include an antibody and a probe covalently-linked to the antibody. The antibody has an antigen-binding site that selectively binds the molecule of interest and a purine-binding site, which is at a location distinct from that of the antigen-binding site. The probe includes a purine molecule, which is covalently bound at the purine-binding site to the antibody, and a label linked to the purine molecule. Upon binding of the molecule of interest to the biosensor antigen-binding site, the biosensor undergoes a conformational change, which detectably alters a signal of the label such that the molecule of interest can be detected.09-22-2011
20090208419Multimodality Imaging of Reporter Gene Expression Using a Novel Fusion Vector in Living Cells and Animals - Novel double and triple fusion reporter gene constructs harboring distinct imagable reporter genes are provided, as well as applications for the use of such double and triple fusion constructs in living cells and in living animals using distinct imaging technologies.08-20-2009
20080233051Nanoparticles for two-photon activated photodynamic therapy and imaging - The present invention provides organically modified silica (ORMOSIL) nanoparticles into which have been incorporated two-photon absorption dye molecules. The two photon absorption dye displays a unique aggregation induced fluorescence enhancement behavior. As a result ORMOSIL nanoparticles with high amounts of the dye can be prepared. These particles can be used for imaging. In one embodiment, the nanoparticles can additionally have incorporated therein a photosensitizer. The photosensitizer can be activated by intraparticle fluorescence resonance energy transfer (FRET) from the dye aggregates resulting in enhanced fluorescence and singlet oxygen generation from photosensitizer under two-photon excitation conditions. Such nanoparticles can be used for photodynamic therapy applications.09-25-2008
20090004117Self-Illiminating Dot Systems and Methods of Use Thereof - Generally, aspects of the present disclosure are directed to conjugate systems, self-illuminating quantum dot conjugates, methods of detecting a target in a host, methods of treating a disease in a host, and the like.01-01-2009
20090214436DICHROMIC FLUORESCENT COMPOUNDS - The present invention provides dichromic fluorescent compounds, as well as processes for making and methods for using the dichromic fluorescent compounds.08-27-2009
20110223109DIAGNOSTIC SUBSTANCE FOR USE IN A METHOD FOR DETERMINING THE AGGRESSIVENESS OF A PROSTATE TUMOR AND DIAGNOSTIC METHOD - In order to determine the aggressiveness of a prostate tumor, a diagnostic substance is administered to a patient that includes a biomarker provided with a first label that is detectable with a detection device and that specifically binds to a VEGF molecule, and that contains a biomarker that binds specifically to a target molecule that occurs uniformly in the endothelium of blood vessels of healthy tissue and the blood vessels of a prostate tumor, and that is provided with a second label that is detectable with the detection device independently of the first label.09-15-2011
20090220430Fluorescent Imaging Agents - Provided is a family of intramolecularly quenched imaging agents for use in both in vivo and in vitro imaging that contain at least one enzymatically cleavable oligopeptide and two fluorophores or a fluorophore and a quencher. When subjected to proteolytic cleavage, at least one fluorophore is unquenched and becomes capable of producing a fluorescent signal upon excitation with light of an appropriate wavelength. Also provided are in vivo and in vitro imaging methods using such imaging agents.09-03-2009
20100003196FLUORESCENT MEMBRANE INTERCALATING PROBES AND METHODS FOR THEIR USE - The invention relates to a family of cyanine dyes which fluoresce in the far red and near infra red wavelengths of the spectrum and preferably possess lipophilic side chains. The dyes of the invention are soluble in commercially available membrane staining vehicles, are useful as probes for rapidly staining lipophilic structures such as membranes in cells or isolated from cells, and are well retained therein. Methods of using the dyes to detect stained cells both in vivo and in vitro are also disclosed.01-07-2010
20100178251Dual-Sensitizer-Containing Luminescent Compounds, Conjugates, and Uses Thereof - The invention relates to novel luminescent compositions of matter containing two fluorophores (sensitizers), synthetic methods for making the compositions, macromolecular conjugates of the compositions, and the use of the compositions and their conjugates in various methods of detection. The invention also provides kits containing the compositions and their conjugates for use in the methods of detection.07-15-2010
20100178252PRODUCTS AND METHODS FOR DISCLOSING CONDITIONS IN THE ORAL CAVITY - An oral composition capable of identifying a condition within the oral cavity by causing a visual contrast between the condition and the hard and soft tissues of the oral cavity has at least one disclosing agent. The disclosing agent can fluoresce in order to highlight conditions within the oral cavity.07-15-2010
20100260683THERMOLABILE LIPOSOME WITH CONTROLLED RELEASE TEMPERATURE - The invention relates to a thermolabile liposome with controlled release temperature for the liposome content, which is essentially formed by at least one phosphatidyl choline with a main transition temperature ranging from 0 to 80° C. and 2 to 15 percent by weight of phosphatidyl oligoglycerin.10-14-2010
20100189660METHODS FOR THE DETECTION OF FATTY-ACYLATED PROTEIN - Sensitive, non-radioactive fatty-acyls of Formula I are useful in in vivo methods for detection and cellular imaging of a fatty-acylated substrate (e.g., protein or polypeptide).07-29-2010
20100189659DIAGNOSTIC SUBSTANCE AND METHOD FOR THE DIAGNOSIS OF PROSTATE DISEASES - A diagnostic substance for use in a method for diagnosing prostate diseases contains multiple different coupling molecules that respectively bind to signal molecules (target molecules) of a molecular surface structure of a pathological tissue that is associated with a prostate disease. A first of the coupling molecules specifically binds to signal molecules of cancer tissue, and a second of the coupling molecules specifically binds to signal molecules formed in inflamed tissue. First and second markers are respectively associated with the first and second coupling molecules, the first and second markers being detectable, and differentiated from each other, with a detection device.07-29-2010
20100189658Imaging probes - The present invention relates to molecular probes of the formula (I)07-29-2010
20100189657INTRAMOLECULARLY QUENCHED FLUOROCHROME CONJUGATES AND METHODS OF USE - The invention provides a quenched fluorochrome conjugate and methods of use thereof in the detection and treatment of disorders characterized by unwanted cellular proliferation including cancer.07-29-2010
20110104070SITE SPECIFIC FLUORESCENCE AND CONTRAST MARKER FOR SAME - A contrast marker for indicating a presence of a target cell in an environment comprises a fluorophore, an NMP, and a short spacer and a long spacer linking the fluorophore to the NMP. The short spacer holds the fluorophore at a quenching distance from the NMP and the long spacer holds the fluorophore at a fluorescence enhancing distance from the NMP. The short spacer is configured to be cleaved by a molecule characterizing the target cells.05-05-2011
20100239502IN VIVO EXPRESSION ANALYSIS USING ULTRASOUND-INDUCED TRANSFECTION OF REPORTER CONSTRUCTS - The invention features compositions and methods for in vivo expression analysis. The data presented herein demonstrates that ultrasound-enhanced delivery and/or expression of a composition for expression analysis comprising microbubbles vectors as well as a genetic payload, comprising a “always-on” promoter, a “reference” reporter gene, a “query” promoter and an “answer” reporter gene, enables in vivo analysis of gene expression both without requiring prior preparation (especially genetic modification) of the test subject (animal or patient) and without causing long term or systemic effects on the subject. Such an invention can be used, for example, to query the epigenotypic or phenotypic response of the individual subject to a foreign effector substance such as a pyrogen, pharmaceutical compound, pharmaceutical lead compound, an allergen, an autoimmunogene, a toxin, a polyclonal antibody, a monoclonal antibody, an antigen, a lipid, a carbohydrate, a peptide, a protein, a protein-complex, an amino acid, a fatty acid, a nucleotide, DNA, RNA, PNA, siRNA and micro RNA.09-23-2010
20100150843PEPTIDE IMAGING AGENTS - The present invention relates to labelled cMet binding peptides suitable for optical imaging in vivo. The peptides are labelled with an optical reporter group suitable for imaging in the red to near-infrared region. Also disclosed are pharmaceutical compositions and kits, as well as in vivo imaging methods, especially of use in the detection, staging, diagnosis, monitoring of disease progression or monitoring of treatment of colorectal cancer (CRC).06-17-2010
20110059023NARROWBAND IMAGING USING NEAR-INFRARED ABSORBING NANOPARTICLES - Devices and methods are provided for image identification of contrast agents comprising nanopartiles. The imaging devices and methods may also be configured to identify target tissues from surrounding tissues such as disease conditions (e.g. cancer tumors) through narrow-band imaging of tissue. Contrast agents such as near-infrared absorbing nanoparticles may be introduced to an organism to distinguish target cells, tissues, or structures from normal tissue. The contrast agent is allowed to preferentially accumulate in the target cells, tissues or structures. As the contrast agents are adapted to preferentially absorb one or more wavelengths of light, the reflection of one wavelength or band of wavelengths by the contrast agents is compared to a separate wavelength or band of wavelengths to identify the target cells, tissues, or structures. In this way, the comparisons identify the presence of the preferential accumulation of the contrast agent in the target cells, tissues or structures.03-10-2011
20110059022TWO PHOTON TRACER, METHOD FOR THE PREPARATION THEREOF AND THE USE THEREOF IN SCREENING ANTICANCER AGENTS - Disclosed herein are compounds useful as two-photon tracers. Also, methods are provided for visualizing intracellular glucose uptake, screening anticancer agents, and diagnosing cancer using the compounds. They exhibit preferential uptake by cancer cells, penetrability sufficient to allow bright section images, high water solubility, high pH resistance and low toxicity in addition to applicability to living cells in deep tissues over a long period of time.03-10-2011
20100254910METHODS AND COMPOSITIONS FOR DIAGNOSTIC AND THERAPEUTIC TARGETING OF COX-2 - The presently disclosed subject matter provides compositions that selectively bind cyclooxygenase-2 and comprise a therapeutic and/or diagnostic moiety. Also provided are methods for using the disclosed compositions for diagnosing (i.e., by imaging) a target cell and/or treating a disorder associated with a cyclooxygenase-2 biological activity.10-07-2010
20100226861TOPICAL COMPOSITION DETECTION - Compositions, devices, methods, and kits are provided for determining the presence of topical compositions on surfaces, such as skin.09-09-2010
20100233091Pyrazine Derivatives with Extended Conjugation and Methods of Using the same in Optical Applications - The present invention relates to pyrazine derivatives capable of absorbing and emanating spectral energy in the visible and/or near infrared spectrum. Pyrazine derivatives of the invention may be administered to a patient in the form of a pharmaceutically acceptable composition and utilized in medical (e.g., diagnostic imaging) procedures.09-16-2010
20130216482METHODS AND COMPOSITIONS FOR NON-INVASIVE, DYNAMIC IMAGING OF INTESTINAL MOTILITY - Described are methods and composition for use in non-invasive imaging of intestinal structure and function. These methods can be used to identify, diagnose, assess, monitor and direct therapies for gastrointestinal diseases and disorders. Embodiments of the methods utilize highly sensitive optical imaging and fluorescent spectroscopy techniques to track or monitor packets of organic dye excreted in bile into the intestinal tract to provide quantitative information regarding intestinal propulsion and function.08-22-2013
20100221188Coated sensors and methods related thereto - The invention provides coated sensors for detecting the presence of analytes. The sensor comprises one or more fluorescent sources, such as one or more quantum dots or one or more fluorescent dyes, a polymeric matrix, a surface coating, and one or more analyte sensing components. The surface coating may be a conformal polymeric film, permeable to the analyte, which may be deposited via a solventless process such as initiated chemical vapor deposition or photoinitiated chemical vapor deposition. The surface coating may increase the biocompatibility of the sensor, reduce nonspecific protein adsorption, and/or sequester functional sensor components within the sensor. The invention also provides methods for detecting the presence of an analyte with coated sensors of the invention.09-02-2010
20090074672Tumor Boundary Imaging - Tumor boundaries and wound healing are optically imaged by cross-linking a fluorescently-labeled tissue transglutaminase substrate into extracellular matrix.03-19-2009
20120034168Isolated Monoclonal Antibody or Fragment Thereof Binding Prostate Specific Membrane Antigen, Conjugates and Uses Thereof - An isolated monoclonal antibody or fragment thereof binding prostate specific membrane antigen (PSMA) preferably in its native form on the surface of tumour cells. A conjugate of the antibody with an active ingredient and modified forms of the antigen-binding antibody fragment are also provided. The complete antibody and the antigen-recognising fragment thereof are used alone or conjugated for the treatment and the diagnosis of tumours or tissues associated to the tumour overexpressing the PSMA antigen, preferably prostatic neoplastic diseases.02-09-2012
20100015056Uranium-chelating peptides and uses thereof - The invention concerns uranium-chelating peptides as well as their uses for decontaminating soils and water, and for detecting and treating people contaminated by uranium. Said peptides have a helix-loop-helix type structure comprising the sequence of a calmodulin loop including at least one mutation of neutral residues selected from the group consisting of S, T, C, H, Y, N and Q, of one, two or three residues of at least one of the four calmodulin calcium binding sites: site I: residues selected among D20, D22 and D24 residues; site II: residues selected among D56, D58 and N60 residues; site III: residues selected among D93, D95 and N97 residues; site IV: residues selected among D129, D131 and D133 residues; said positions being indicated with reference to the human calmodulin sequence.01-21-2010
20080292556Target Vector with Activable Imaging Function - The invention concerns the field of molecular probe architecture for in vivo imaging. More particularly, the invention concerns molecular constructs providing an imaging function activable in intracellular environment, said constructs being further bound to a vector which enables certain cells to be targeted, and said cells to be internalized. The inventive fluorescence probes enable in particular images of certain targeted tissues to be formed, while maintaining a low background noise level and, preferably, while obtaining at the targeted tissue, an imaging signal increasing in time.11-27-2008
20110104069MULTI-FUNCTIONAL BIODEGRADABLE PARTICLES FOR SELECTABLE TARGETING, IMAGING, AND THERAPEUTIC DELIVERY AND USE THEREOF FOR TREATING OCULAR DISORDERS - In various embodiments, provided are multi-functional biodegradable particles for selectable targeting, imaging, and delivery of therapeutic agents. Also provided are methods of using the provided particles for treatment of ocular disorders, such as for the treatment of age-related macular degeneration. The provided particles and methods provide a clinician with options for control over, and monitoring of, the delivery of therapeutic agents.05-05-2011
20130129631Fluorescent Probe for Imaging Lymph Nodes - Disclosed is a near-infrared fluorescent imaging agent comprising an indocyanine-based fluorescent dye and a liposome. The near-infrared fluorescent imaging agent of the present invention demonstrates high fluorescence intensity and a long anchoring time in sentinel lymph nodes, thereby making it useful for detecting sentinel lymph nodes in sentinel lymph node navigation surgery. Also disclosed is an indocyanine green derivative that is particularly suitable for use in the near-infrared fluorescent imaging agent of the present invention.05-23-2013
20100297024PROMOTER INDUCIBLE BY REACTIVE OXYGEN SPECIES AND VECTOR COMPRISING THE SAME - The invention provides promoters inducible by reactive oxygen species (ROS), capable of driving the expression of a gene of interest, particularly in a tumor cell. More particularly, it refers to promoters inducible by reactive oxygen species, that may be used to drive the expression of a gene of interest, such as a therapeutic gene, or a reporter gene for use in image diagnosis. The promoters comprise at least a fragment of a promoter sequence responsive to said reactive oxygen species, and corresponding to a gene highly expressed in cancer cells, wherein the fragment of the promoter sequence responsive to reactive oxygen species (ROS) is selected from the group of: the VE element of the VEGF promoter, the E6 element of the promoter of the EGR-1 gene, the MMP-1 element and a chimeric promoter containing an E6 element and a VE element. It also provides vectors carrying a human therapeutic or non therapeutic gene of interest, operably linked to said promoter sequence and compositions comprising the same.11-25-2010
20110117026METHODS AND COMPOSITIONS FOR THE DELIVERY OF BIOACTIVE COMPOUNDS - The present invention provides compositions comprising delivery systems comprising a lipid vehicle, a bioactive compound, and a polyanionic carrier macromolecule that is not a carrier polynucleotide, wherein the lipid vehicle encapsulates the polynucleotide of interest and the polyanionic carrier macromolecule, and wherein the delivery system is essentially free of carrier polynucleotides. Compositions also include delivery systems comprising a lipid vehicle and a bioactive agent, wherein the lipid vehicle encapsulates the bioactive agent, and wherein the lipid vehicle comprises a covalent bilayer or a core supported bilayer comprising polycationic lipids. Other compositions provided herein comprise a delivery system comprising a polypeptide of interest and a means for delivering the polypeptide into a cell. Also provided herein are methods for making the delivery systems, methods for delivering bioactive compounds, methods for treating a disease or unwanted condition in a subject with the delivery systems, and methods for detecting apoptosis in a cell.05-19-2011
20100303728CASPASE IMAGING PROBES - The present invention relates to molecular probes of formula (I)12-02-2010
20130136697INJECTABLE DENDRIMER HYDROGEL NANOPARTICLES - The invention discloses injectable hydrogels which are in the form of crosslinked nano beads or particle in the size range 5 nm to 10 μm, comprising PAMAM dendrimer with asymmetrical peripheral end groups such that one of the terminal groups is involved in formation of hydrogel and the other in involved in the conjugation of drugs or imaging agents and their methods of preparation. The said gel is formed by reaction of the PAMAM dendrimer with asymmetrical end groups with other polymer wherein the other polymer is selected from the group of linear, branched, hyperbranched or star shaped polymers with functionalized terminal groups. The PAMAM dendrimer with asymmetrical terminal groups consists of a Generation 2 and above PAMAM dendrimer with symmetrical end groups modified using the amino acids or their modified forms. The gel disclosed in the present invention is formed as small crosslinked particles in the size range 25 nm to 10 μm and is suitable for injectable delivery of hydrogel to any of the body orifices, tissues by intramuscular or subcutaneous route and ocular delivery for the purpose of therapeutic treatment and imaging.05-30-2013
20110110864FLUORESCENT NANOCRYSTALS ENCAPSULATED IN AN INORGANIC SHELL - The present invention relates to a method of preparing hybrid organo/mineral nanoparticles comprising an organic fluorescent crystalline core encapsulated in an inorganic shell, and to nanoparticles that can be obtained by said method. The method of the present invention comprises the following steps: (i) a sol-gel mixture able to be obtained by a process comprising the addition, in at least one organic solvent, in the presence of water, of a fluorescent organic compound and at least one metal alkoxide is sprayed; (ii) the sprayed sol-gel mixture is dried, by evaporating the solvent and the water that are present in the sol-gel mixture. The nanoparticles of the present invention can be used for example as a tracer in medical imaging or as a chemical sensor.05-12-2011
20100329989In Vivo Labeling of Mammalian Cone Photoreceptors by Intravitreal Injection of Fluorescently Tagged Peanut Agglutinin - A method for specifically labeling of mammalian cone photoreceptors in vivo comprising injecting a mammal with peanut agglutinin conjugated with a fluorescent probe. The peanut agglutinin labels the cone photoreceptor.12-30-2010
20090214435Recombinant vector expressing MDR1 shRNA and thymidine kinase and use thereof - A recombinant vector capable of expressing MDR1 shRNA and thymidine kinase, and a use thereof. More specifically, provided is a recombinant vector capable of efficiently expressing MDR1 shRNA and thymidine kinase in a host cell, a transfectant cell comprising the same recombinant vector, a composition for treating neoplastic diseases, comprising the same recombinant vector, and a method for imaging of neoplastic lesions using the same recombinant vector. The recombinant vector of the present invention is capable of achieving efficient intracellular expression of MDR1 shRNA and a thymidine kinase-GFP fusion protein within the host cell and is therefore highly effective for combined therapy of anticancer drugs. Further, the recombinant vector of the present invention enables imaging of neoplastic lesions. Therefore, the recombinant vector of the present invention can be used in combination with other anticancer drugs for treatment of neoplastic diseases.08-27-2009
20090068113AMPHIPHILIC SQUARAINE DYES, PROCESS FOR PREPARATION THEREOF AND USE THEREOF - The present invention relates to amphiphilic squaraine dyes of the general formula (1) as shown below Formula (1) wherein, R03-12-2009
20110008262DRUG DELIVERY SYSTEM TARGETING TO ESTROGEN RECEPTOR OVER-EXPRESSED CELLS - A vector for targeted delivery of drugs into estrogen receptors over-expressed cells is disclosed. The vector of the present invention is mainly about an active targeting delivery carrier which consists of a plurality of nanoparticles including: (i) a plurality of targeted moiety conjugated to the outer surface of the nanoparticles, the moiety being capable of binding with the estrogen receptor of a target cell, and (ii) bioactive agents encapsulated in the nanoparticles or forming complex with the nanoparticles. The targeted moiety of the present invention can also be conjugated to parent drugs for prodrug design.01-13-2011
20110129424FLUORINATED POLYMERS AND ASSOCIATED METHODS - Compositions comprising a fluorinated polymer and related methods.06-02-2011
20110033389Modified antibodies for passive immunotherapy - Provided herein are modified therapeutic antibodies containing a protein transduction domain conjugated to a neutralizing antibody. Also provided are methods for generating the modified therapeutic antibodies and methods of using the modified therapeutic antibodies for prevention and treatment of disease.02-10-2011
20110044910IN VIVO FLOW CYTOMETRY BASED ON CELLULAR AUTOFLUORESCENCE - The present invention generally provides methods and systems for performing in vivo flow cytometry by using blood vessels as flow chambers through which flowing cells can be monitored in a live subject in vivo without the need for withdrawing a blood sample. In some embodiments, one or more blood vessels are illuminated with radiation so as to cause a multi-photon excitation of an exogenous fluorophore that was previously introduced into the subject to label one or more cell types of interest. In some other embodiments, rather than utilizing an exogenous fluorophore, endogenous (intrinsic) cellular fluorescence can be employed for in vivo flow cytometry. The emission of fluorescence radiation from such fluorophores in response to the excitation can be detected and analyzed to obtain information regarding a cell type of interest.02-24-2011
20110117024NANOCARRIER AND NANOGEL COMPOSITIONS - Novel classes of multi-arm polyalkylene oxide-based materials including PEG nanocarriers, nanogel particles, and aggregated nanogel particles are disclosed. These classes of compositions may be associated with therapeutic agents and targeting moieties, or visibility enhancing agents, and may have a modified surface structure. In some embodiments the PEG-based materials can be made to provide relatively high drug loads with improved solubility and targeted delivery.05-19-2011
20110117025DEVICE AND METHOD FOR FLUORESCENCE-BASED IMAGING AND MONITORING - A device for fluorescence-based imaging and monitoring of a target comprising: a light source emitting light for illuminating the target, the emitted light including at least one wavelength or wavelength band causing at least one biomarker associated with the target to fluoresce; and a light detector for detecting the fluorescence.05-19-2011
20110085986Diagnosis and treatment of epithelial cancers using labeled/conjugated progastrin peptides - The current invention provides Progastrin peptides that specifically bind Annexin A2 overexpressed by epithelial cancers. The invention includes isolated homing Progastrin peptides conjugated to an imaging agent and methods of using the same for the diagnosis of epithelial cancers. Also encompassed are Progastrin peptides conjugated to cytotoxic agents such as Camptothecin, Doxorubicin, Paclitaxel and derivatives thereof, and methods of treating epithelial cancer using the same.04-14-2011
20100178253PEPTIDE IMAGING AGENTS - The present invention relates to labelled cMet binding peptides suitable for optical imaging in vivo. The peptides are labelled with a benzopyrylium dye suitable for imaging in the red to near-infrared region. Also disclosed are pharmaceutical compositions and kits, as well as in vivo imaging methods, especially of use in the detection, staging, diagnosis, monitoring of disease progression or monitoring of treatment of colorectal cancer (CRC).07-15-2010
20100008860COLOR-MARKED OLIGOSACCHARIDES OR POLYSACCHARIDES - The invention concerns color-marked oligosaccharides or polysaccharides, procedures for the synthesis of these color-marked oligosaccharides or polysaccharides and their use in the determination of kidney function.01-14-2010
20100055039NON-INVASIVE METHODS OF MONITORING ENGRAFTED STEM CELLS AND METHODS FOR ISOLATION OF SKELETAL MUSCLE STEM CELLS - The embodiments of the present disclosure encompass methods for non-invasive in vivo bioluminescence imaging that allow the dynamics of stem cell behavior to be followed in a manner not possible using conventional retrospective static histological analyses. By imaging luciferase-generated bioluminescence activity emanating from isolated stem cells, for example, real time quantitative and kinetic analyses can show that donor-derived muscle stem cells may proliferate and engraft rapidly after injection until homeostasis is reached. In addition, the response of the stem cells to injury and participation in the regenerative response can be monitored over time. Other aspects of the disclosure encompasses methods for determining the suitability of a stem cell for tissue replacement, methods for repairing muscle injury, and methods for isolating muscle stem cells from a tissue sample.03-04-2010
20110250144RGD-CONTAINING PEPTIDOMIMETICS AND USES THEREOF - The invention provides RGD-containing cyclic peptidomimetics; conjugates of said peptidomimetics and a moiety of a payload selected from fluorescent probes, photosensitizers, chelating agents, or cytotoxic agents; and pharmaceutical compositions comprising these conjugates. The conjugates of the invention are useful both for diagnostic purposes and treatment of various diseases, disorders and conditions. More specifically, conjugates comprising fluorescent probes can be used for diagnostic purposes, e.g., visualization of organs and tissues, and diagnosis of tumors; conjugates comprising photosensitizers can be used for photodynamic therapy of both tumors and nonneoplastic tissues; conjugates comprising chelating agents can be used in radio imaging or radiotherapy; and conjugates comprising cytotoxic agents can be used for in targeted chemotherapy.10-13-2011
20110104071METHODS AND SYSTEMS FOR SPATIALLY IDENTIFYING ABNORMAL CELLS - The present invention provides compositions and methods for imaging tumor resections.05-05-2011
20110070166REDUCED DYE PROBES FOR THE DETECTION OF RADICAL OXYGEN SPECIES - Reduced dyes, such as hydrocyanines, deuterocyanines, and/or other deuterated dyes capable of detecting one or more reactive oxygen species are described herein. The reduced dyes exhibit little or no fluorescence due to the disrupted π conjugation. However, upon reaction with ROS, the reduced dyes are oxidized, regenerating the extended π conjugation and causing a substantial increase in fluorescence intensity. In many case, the oxidized dye is generally membrane impermeable. However, upon reduction, many of the reduced dyes are membrane permeable. Thus, reduced dyes can accumulate in cells and/or tissue to amplify the signal. Once inside the cell or tissue, the reduced dye is reoxidized upon reaction with ROS, and the oxidized dye again becomes membrane impermeable, trapping the dye within the cell. The reduced dyes can be used to image ROS, such as hydroxide radical and superoxide, in serum, cell cultures, tissue explants, and in vivo.03-24-2011
20110250145BIOLUMINESCENCE IMAGING OF MYELOPEROXIDASE ACTIVITY IN VIVO, METHODS, COMPOSITIONS AND APPARATUSES THEREFOR - Methods of imaging distribution of myeloperoxidase activity in a subject are disclosed. These methods include the use of bioluminescent substrates, including luminol and wavelength-shifted analogues of luminol. Bioluminescent myeloperoxidase substrates that emit light at longer wavelengths compared to luminol are shown to be useful for imaging myeloperoxidase activity in vivo. The disclosed methods can be used for imaging sites of inflammation and other pathological conditions associated with abnormal levels of MPO activity in vivo. Methods of synthesis of luminol analogues are also disclosed.10-13-2011
20080253968IN VIVO EXAMINATION METHOD - It is possible to perform quantitative examination of biological tissue even with a solution composed of a near-infrared fluorescent dye and a polypeptide. An image acquired before administering a reagent is subtracted from an image acquired after administering the reagent to remove regions appearing in both images, such as autofluorescence, thus obtaining an image in which only detected fluorescence affected by administration of the reagent is extracted. Because tumors have many (leaky) blood vessels, regions having many areas of high intensity in the extracted image can be recognized as tumors.10-16-2008
20100303727OPTICAL IMAGING AGENTS - The present invention relates to imaging agents suitable for in vivo optical imaging, which comprise conjugates of pentamethine cyanine dyes having reduced non-specific binding, e.g. to plasma proteins. This is achieved by control of the nature and location of the sulfonic acid substituents, in particular the sulfoalkyl groups. Also disclosed are pharmaceutical compositions and kits, as well as in vivo imaging methods.12-02-2010
20090317334OPTICAL DETECTION METHOD OR IMAGING METHOD OF IMPLANTED CELLS - There is provided a method of an animal model experiment to observe cells implanted to an experimental small animal in which the position or spatial spread only of the implanted cells can be detected and observed with time progress and with sufficient accuracy while a plurality of kinds of the implanted cells can be distinguished from one another. The inventive method of in vivo detecting implanted cells implanted into the body of a small animal comprises steps of preparing cells used as the implanted cells into which a gene expressing a tag of a part of a peptide or a protein on a cell membrane is introduced; implanting the implanted cells to an arbitrary site of the small animal; and detecting the tags in the small animal. The tags may be detected by dosing the small animal with fluorescently labeled antibodies to the tags and imaging the fluorescence from the antibodies.12-24-2009
20090317333PROTEIN KINASE A REPORTERS USEFUL IN HIGH THROUGHPUT ASSAYS - Protein kinase A reporters useful for obtaining measurements of protein kinase A activity with high spatial and temporal resolution can be used in high throughput assays to identify potentially therapeutic compounds.12-24-2009
20110158914FLUORESCENCE IMAGE CAPTURING METHOD AND APPARATUS - A fluorescence image capturing apparatus for capturing a fluorescence image by receiving fluorescence emitted from an observation area administered with a fluorescent agent, in which pharmacokinetic information of the fluorescent agent is obtained and the intensity of the excitation light and/or the charge storage period of the image sensor is controlled based on the pharmacokinetic information of the fluorescent agent.06-30-2011
20080279780Fluorescent chlorotoxin conjugate and method for intra-operative visualization of cancer - A chlorotoxin conjugate detectable by fluorescence imaging that allows for intra-operative visualization of cancerous tissues, compositions that include the chlorotoxin conjugate, and methods for using the chlorotoxin conjugate.11-13-2008
20090004116IN VIVO OPTICAL IMAGING - Provided herein are methods for imaging an optically labeled target cell implanted in vivo using a reporter construct that encodes an enzyme that is not endogenous to the target cell. The disclosed methods include the steps of: (a) introducing target cell transformed with non-endogenous enzyme into a mammalian subject; (b) contacting the transformed target cell with a cell-permeable soluble fluorescent dye; and (c) observing a fluorescent signal generated by the target cell present in the mammalian subject. In some embodiments, the non-endogenous enzyme comprises a nitroreductase. In some embodiments, the methods may also include the step of tracking the fluorescent target cells in the mammalian subject over time.01-01-2009
20110256065Non-Isotopic Detection of Osteoblastic Activity In Vivo Using Modified Bisphosphonates - The present invention is directed to a non-isotopic methods for the in vitro and in vivo detection of hydroxyapatite-positive cells and structures.10-20-2011
20110165085TUMOR SELECTIVE FLUORESCENT STAINING AGENT - A tumor cell or tumor tissue-selective fluorescent staining agent comprising a compound represented by the following general formula (I):07-07-2011
20110165083Peptides that home to tumor lymphatic vasculature and methods of using same - The present invention provides a conjugate containing a moiety linked to a homing molecule that selectively homes to tumor lymphatic vasculature. The invention also provides a method of directing a moiety to tumor lymphatic vasculature in a subject by administering to the subject a conjugate containing a moiety linked to a homing molecule that selectively homes to tumor lymphatic vasculature.07-07-2011
20110165084VIVO DETECTION OF PHOSPHOLIPASE ACTIVATION - The present invention is directed to a phospholipid-based NIR molecular beacon, having a phospholipid moiety; with an NIR fluorophore moiety covalently linked to a phospholipid glycerol backbone and a quencher moiety covalently linked to the phospholipid glycerol backbone. Additionally, provided herein is methods of analyzing a sample for the presence of a phospholipase and methods of identifying the activity of a phospholipase in vivo utilizing phospholipid-based NIR molecular beacon.07-07-2011
20110020241FLUORESCENT LABELING AGENT CONTAINING QUANTUM DOTS - Disclosed is a fluorescent labeling agent containing quantum dots, which exhibits little fluctuation in luminous properties in accordance with the environment where the fluorescent labeling agent is stored and therefore has high environmental stability, and which has high luminous intensity. Specifically disclosed is a fluorescent labeling agent containing quantum dots, which comprises: (1) a fluorescent labeling agent core part which comprises at least three quantum dots per a fluorescent labeling agent and a protective material; and (2) an organic surface-coating layer which coats the fluorescent labeling agent core part, wherein the fluorescent labeling agent core part has an average particle diameter of 10 to 50 nm.01-27-2011
20110020239METHODS FOR IN VIVO IMAGING OF CELLS - The instant invention provides methods for the in vivo imaging of cells using one or more imaging modalities.01-27-2011
20110027191OPTICAL IMAGING AGENT - The near-infrared wavelengths (700 nm-900 nm) are a suitable optical window for light penetration and deep tissue imaging. The present invention provides a near-infrared fluorescent blood pool contrast agent. The agent is of use to detect and quantify pathological capillary leak in live animals, e.g., serially imaging of traumatized tissue (muscle) as well as tumors.02-03-2011
20100284929FLUORESCENT IMAGING OF TUMORS USING PHOSPHOLIPID ETHER COMPOUNDS - The invention generally relates to the use of novel fluorescent phospholipid ether compounds and compositions comprising these compounds in fluorescence imaging of tumors. A preferred compound of the present invention has the following structural formula:11-11-2010
20100284932FLUORESCENT EMULSIONS FOR OPTICAL IMAGING - The invention relates to a fluorescent emulsion, to a diagnostic reagent containing the same, and to the use thereof in the preparation of a diagnostic reagent for in vivo fluorescence imaging.11-11-2010
20100284930FLUORESCENT IMAGING OF SKIN CANCERS USING PHOSPHOLIPID ETHER COMPOUNDS - The invention generally relates to novel fluorescent phospholipid compounds, compositions comprising these compounds, and their use in a variety of diagnostic applications, including fluorescence imaging of tumors. A preferred compound of the present invention has the following structural formula:11-11-2010
20100284931FLUORESCENT PHOSPHOLIPID ETHER COMPOUNDS, COMPOSITIONS, AND METHODS OF USE - The invention generally relates to novel fluorescent phospholipid compounds, compositions comprising these compounds, and their use in a variety of diagnostic applications, including fluorescence imaging of tumors. A preferred compound of the present invention has the following structural formula:11-11-2010
20100329990LUMINESCENT MARKERS - The invention relates to luminescent proteins, nucleic acids encoding same, compositions and combinations comprising the proteins, and methods using the proteins, nucleic acids, compositions and combinations. In particular, a luminescent protein is provided comprising oncomodulin in which a salt bridge has been introduced to provide greater stability. The protein may be used as a luminescent marker in, for example, luminescent items, immunoassays, and fluorescent energy transfer assays.12-30-2010
20110262364Fluorescent Particles Comprising Nanoscale ZnO Layer and Exhibiting Cell-Specific Toxicity - A core-shell nanoparticle having a core that includes a fluorophore and a first oxide of a first metal and a shell that includes a second oxide of a second metal such that the first oxide and the second oxide are different. Also disclosed are methods relating to the core-shell nanoparticle.10-27-2011
20100322866DEVICE, SYSTEM AND METHOD FOR IN-VIVO ANALYSIS - A method for detecting the presence of a substance such as an antigen, the method including the steps of: maintaining a signaling material at a first pH within a liposome; contacting the liposome with a sample having a second pH such that if the substance is present in the sample the liposome will rupture thereby exposing the signaling material to the second pH; and detecting a change in an optical property, such as color, of the signaling material, the change caused by the exposure to the second pH.12-23-2010
20100166663PROBE FOR A HAIR CELL, AND LABELLING METHOD FOR A HAIR CELL USING THE PROBE FOR A HAIR CELL - Provided are a novel probe for a hair cell for clearly identifying various conditions of a hair cell, and a labelling method for a hair cell using the probe for a hair cell, more particularly, a probe for a hair cell containing, as an active agent, at least one kind selected from staining compounds represented by one of the general formulae (I) and (II), and a labelling method for a hair cell using the probe for a hair cell.07-01-2010
20090208418SUPERANTIBODY SYNTHESIS AND USE IN DETECTION, PREVENTION AND TREATMENT OF DISEASE - Superantibodies having enhanced autophilic, catalytic, and/or membrane-penetrating properties are prepared by affinity-based conjugation of a photoactivatable organic molecule to a target immunoglobulin. The photoactivatable organic molecule bears a chromophoric aromatic hydrocarbon moiety, which has affinity for the immunoglobulin. Upon photolysis, the organic molecule is covalently linked to the immunoglobulin. A preferred organic molecule is a peptide and a preferred aromatic hydrocarbon moiety is a tryptophan residue. The photoactivatable organic molecule need not bear a purine, pyrimidine or azido group to effect binding to the immunoglobulin and/or photoactivation. The superantibodies can enhance the potency and expand the targeting range of target antibodies. Autophilic superantibodies can promote apoptosis of target cells and/or enhance therapeutic efficacies in the treatment of patients with diseases or disorders responsive to antibody therapy. Exemplary of such diseases are atherosclerosis and cardiovascular disease. Membrane-penetrating superantibodies can prevent apoptosis by binding to intracellular anti-caspase signal proteins. Compositions containing the superantibodies, as well as methods of making and using them, are disclosed.08-20-2009
20110189101FLUORESCENT LABELING AGENT AND FLUORESCENT LABELING METHOD - Disclosed is use of zinc oxide nanoparticles as an exciton emission source in vivo or in vitro. Also disclosed is a fluorescent labeling agent comprising a zinc oxide nanoparticle and a substance capable of selectively binding to a target in vivo or in vitro, wherein the substance is bound to the zinc oxide nanoparticle via at least one binder. Further disclosed is a fluorescent labeling agent comprising a zinc oxide nanoparticle of which the surface is coated with a coating film selected from ZnS, Mg08-04-2011
20100196282OPTICAL IMAGING AGENTS - The present invention relates to imaging agents suitable for in vivo optical imaging, which comprise conjugates of benzopyrylium dyes with biological targeting moieties, such as peptides Also disclosed are pharmaceutical compositions and kits, as well as in vivo imaging methods.08-05-2010
20110305641Compositions And Methods For Treatment Of Angiogenesis-Associated Ocular Disorders - The invention provides methods and compositions for identifying and quantifying pathological changes on the retina.12-15-2011
20090311193METHODS AND REAGENTS FOR IN VIVO IMAGING OF CANCER CELL LINES - Provided are reagents and methods for non-invasive in vivo imaging wherein the reagents comprise targeted carrier molecules conjugated to a NIR reporter molecule. In one aspect the targeted carrier molecule is an antibody, or fragment thereof that has specificity for an antigen in a living body, animal or human. In one embodiment the antibodies are anti-cancer/tumor marker antibodies, organ specific antibodies, tissue specific antibodies, cell type specific antibodies, cell surface specific antibodies, anti-viral antibodies, anti-bacterial antibodies and anti-pathogenic antibodies. The NIR reporter molecules are any fluorescent reporter molecule compatible with in vivo imaging and generally having an excitation wavelength of at least 580 nm.12-17-2009
20100310468RECOMBINANT ALBUMINS FUSED WITH POLY-CYSTEINE PEPTIDE AND THE METHODS FOR PREPARING THE SAME - The present invention relates to recombinant albumins fused with poly-cysteine peptide and methods for preparing the same, more precisely recombinant albumins in which cysteines that can be used for drug binding are amplified at N-terminal and C-terminal of the albumin and methods for preparing the same. The recombinant albumin of the present invention demonstrates improved albumin-drug conjugation efficiency when it is used for drug delivery system, indicating that it can effectively deliver a large amount of drug to a target tissue. At the same time, the recombinant albumin of the present invention can be used as an excellent drug deliverer with reduced side effects, compared with the conventional albumin carriers, by regulating the amount of drug conjugated to each unit of albumin by regulating the number of cysteine fused thereto. In addition, the recombinant albumin of the present invention can be used for the screening of a novel drug and for the non-invasive real-time diagnosis and treatment of disease by combining with a fluorescent material or a contrast agent for molecular imaging.12-09-2010
20090232742METHOD FOR SCREENING AGENT WITH ANGIOGENIC-MODULATING ACTIVITIES USING TELEOST EMBRYO - This invention relates to a method of 3-tier system for screening compounds, herb extract or extract of herb combination in formula with angiogenic-modulating activities using transparent teleost embryos as model.09-17-2009
20120039813INTRINSICALLY COLORED, LUMINESCENT SILK FIBROIN AND A METHOD OF PRODUCING THE SAME - This present invention proposes a method of producing intrinsically colored, luminescent silk fibroin by feeding silkworms with feed comprising the luminescent dyes as well as the appropriate degumming process to remove sericin while retaining the dyes in silk fibroin are also described. Luminescent and functional molecular organic dyes with balanced hydrophobic/hydrophobic properties that can be effectively absorbed into silk glands of the silkworm are also described.02-16-2012
20120148499PEPTIDES AND APTAMERS FOR TARGETING OF NEURON OR NERVES - The present invention provides methods for guiding preservation of neurons or nerves during surgery by administering a fluorescently-labeled peptide or aptamer that specifically binds to the neurons or nerves. The invention further provides targeting molecules of fluorescently-labeled peptides or aptamers that specifically bind to neurons or nerves and for compositions thereof.06-14-2012
20100209354ORGANIC/INORGANIC HYBRID NANOPARTICULATES MADE FROM IRON CARBOXYLATES - The invention relates to nanoparticles made from organometallic hybrid materials made from iron carboxylates, used for example as contrast agents. The particles can also be used for the encapsulation and vectoring of molecules of interest such as active3 pharmaceutical agents, cosmetically interesting compounds and markers. Apart from the intrinsic properties thereof for imaging, said nanoparticles give good results in terms of capacity for loading with medicaments and in biocompatibility.08-19-2010
20080219933Fluorescence-Mediated Molecular Tomography - This invention relates to a fluorescence-mediated molecular tomographic imaging system, designed to detect near-infrared fluorescence activation in deep tissues. The system can use targeted fluorescent molecular probes or highly sensitive activatable fluorescence molecular probes. Such probes add molecular specificity and yield high fluorescence contrast, to allow early detection and molecular target assessment of diseased tissue, such as cancers, in vivo. The new tomographic imaging system enables three-dimensional localization in deep tissues and quantitation of molecular probes.09-11-2008
20110318273FLUORESCENT CONTRAST AGENTS - The invention relates to contrast agents for imaging of diseases associated with inflammations. More specifically the invention provides optical imaging contrast agents for imaging of activated leukocytes and methods for imaging of such. The contrast agent changes its fluorescent properties upon reaction with oxidants produced by the activated leukocytes.12-29-2011
20120207683EVALUATION PROBE FOR CENTRAL NERVOUS SYSTEM PERMEABILITY, EVALUATION METHOD FOR CENTRAL NERVOUS SYSTEM PERMEABILITY, AND SCREENING METHOD USING AN EVALUATION PROBE FOR CENTRAL NERVOUS SYSTEM PERMEABILITY - Provided is an evaluation probe capable of optically evaluating permeability of a substance through a central nervous system tissue. Also provided is an evaluation method for permeability of a substance through a central nervous system tissue using an evaluation probe for central nervous system permeability. Also provided is a screening method using an evaluation probe for central nervous system permeability. The evaluation probe for central nervous system permeability includes, as an active ingredient, at least one kind of compound represented by the following general formula (1).08-16-2012
20120009126OPTICAL DETERMINATION OF GLUCOSE UTILIZING BORONIC ACID ADDUCTS - The present invention concerns an improved optical method and optical sensing device for determining the levels of polyhydroxyl-substituted organic molecules in vitro and/or in vivo in aqueous media. The range of detection is between about 400 and 800 nm. In particular, a sensory devise is implemented in a mammal to determine sugar levels. Specifically, a dye is combined with a conjugated nitrogen-containing heterocyclic aromatic boronic acid-substituted bis-onium compound in the presence of a sugar, such as fructose or glucose. The viologens are preferred as the aromatic conjugated nitrogen-containing boronic acid substituted compounds. The method is useful to determine sugar levels in a human being.01-12-2012
20090285762IMAGING METHODS AND COMPOSITIONS COMPRISING FLUORESCENT DYES ASSOCIATED WITH VIRAL COMPONENTS FOR NERVE IMAGING - Disclosed herein are compositions and methods for imaging nerve cells. The composition comprises a fluorescent dye; and a viral component selected from a neurotropic, replication-defective virus, a viral protein of a neurotropic virus, and a capsid of a neurotropic virus. Although the fluorescent dye in itself cannot penetrate nerve cells, the fluorescent dye is bound to the viral component to form a dye/viral component complex that is capable of penetrating nerve cells.11-19-2009
20120058052METHOD FOR AVIAN SEX DETERMINATION - The invention relates to a method and apparatus for pre-hatch avian embryo sex determination. In particular, the invention relates to a non-invasive method and apparatus for in-ovo determining the sex of avian species while in the egg and allowing to sort the eggs into groups consisting primarily of either male or female embryos. The method comprises the steps of introducing into the egg an antibody designed to match with a sex specific antigen on the embryo, which antibody is labelled, allowing the labelled antibody to migrate to and bind with the sex specific antigen on the embryo, detecting binding of the labelled antibodies on the embryo using detection means positioned outside of the egg.03-08-2012
20090047219Visible to near-infrared light probe using energy transfer between luciferase and an organic dye via a sugar chain - An object of the present invention is to produce a luminescent probe that has less biological effects, efficiently emits visible to near-infrared light, which is excellent for the imaging of individuals, and the use thereof. The present invention provides a sugar chain-containing-luciferase derivative, wherein an organic fluorescent dye is bonded to the luciferase through the sugar chain.02-19-2009
20120156140FLUORESCENT COMPOUNDS - Compounds used as labels with properties comparable to known fluorescent compounds. The compounds can be conjugated to proteins and nucleic acids for biological imaging and analysis. Synthesis of the compounds, formation and use of the conjugated compounds, and specific non-limiting examples of each are provided.06-21-2012
20120064010CCR3 and its Ligands Are Therapeutic and Diagnostic Targets for Neovascular Age-Related Macular Degeneration - The results presented herein demonstrate the specific expression of CCR3 in CNV endothelial cells in humans with AMD, and despite the expression of its ligands, eotaxin-1, -2, and -3, neither eosinophils nor mast cells are present in human CNV. The genetic or pharmacological targeting of CCR3 or eotaxins as disclosed herein inhibited injury-induced CNV in mice. CNV suppression by CCR3 blockade was due to direct inhibition of endothelial cell proliferation, and was uncoupled from inflammation as it occurred in mice lacking eosinophils or mast cells and was independent of macrophage and neutrophil recruitment. CCR3 blockade was more effective at reducing CNV than vascular endothelial growth factor-A (VEGF-A) neutralization, which is currently in clinical use, and, unlike VEGF-A blockade, not toxic to the mouse retina. In vivo imaging with CCR3-targeting quantum dots located spontaneous CNV invisible to standard fluorescein angiography in mice before retinal invasion. CCR3 targeting is useful in reducing vision loss due to AMD through early detection and therapeutic angioinhibition.03-15-2012
20110081298RATIOMETRIC BIOLUMINESCENT SENSOR FOR IMAGINING OXIDATIVE STRESS - This invention provides a novel ratiometric bioluminescent sensor and methods of use thereof. The bioluminescent sensor comprises two luminescent proteins that exhibit different characteristics associated a biological condition, and thereby illuminates differently in response to the biological condition. A ratio between the luminescence of the two luminescent proteins indicates a change in the biological condition. The bioluminescent sensor of the invention can be used to image an oxidative stress or its associated conditions, including a programmed cell death.04-07-2011
20100291000Diagnostic value of systemic ACE pathway activation in the detection by fluorescence of localized pathological lesions - Alternative cellular energy pigments (ACE-pigments) provide a source of cellular energy other than that provided through the oxidative metabolism of foods, or in the case of plants and certain bacteria, through the process of photosynthesis. In some patients, ACE pigments exist in a form that can be further energized or activated using ultraviolet (UV) light, especially if the reaction is initially triggered by the presence of suitable dyes, such as neutral red. Once partially activated, ACE pigments within a localized lesion will fluoresce upon direct exposure to UV light. It is diagnostically useful to screen an individual or animal undergoing localized or systemic activation of their ACE pathway for the presence of lesions elsewhere in the body, which become fluorescent under direct UV illumination, both as a way of detecting an otherwise non-apparent or unnoticed lesion and of confirming that such a lesion contains ACE pigments that can be further activated. The development of direct UV fluorescence in a localized lesion can also be an indication of the therapeutic value of continuing with direct UV illumination of the lesion.11-18-2010
20100290999NANOPARTICLES OF LIGHT EMISSIVE POLYMERS AND PREPARATION METHOD THEREOF - Disclosed are nanoparticles of a light emissive polymer, comprising nanoparticles of a cyano-substituted poly(arylene vinylene) polymer; and a biocompatible surfactant adsorbed to the surface of the nanoparticles of the polymer, and preparation method thereof, wherein the method comprises: (1) uniformly mixing a dialdehyde monomer represented by a general formula OHC—Ar11-18-2010
20100247446METHOD AND SYSTEM FOR ANALYZING OPTICAL SIGNAL - The present invention is related to a method of analyzing an optical signal which analyzes a signal substance induced by a photosensitive protein, includes the steps of introducing a gene which expresses a luminescent probe to analyze the signal substance into an organism sample, emitting a stimulus light to activate the photosensitive protein, and detecting an optical signal emitted by the organism sample.09-30-2010
20120128596FLUORESCENT PHOSPHOLIPID ETHER COMPOUNDS, COMPOSITIONS, AND METHODS OF USE - The invention generally relates to novel fluorescent phospholipid compounds, compositions comprising these compounds, and diagnostic methods utilizing these compounds. A preferred compound of the present invention has the following structural formula: (I)05-24-2012
20100209353TUMOR TARGETING PROTEIN CONJUGATE AND A METHOD FOR PREPARING THE SAME - The present invention relates to a protein conjugate having excellent tumor targeting capacity and a method for preparing the same, more precisely albumin-bile acid conjugate forming 30-500 nm nano-particles and forming self-aggregates in water system and a method for preparing the same. The albumin-bile acid conjugate of the present invention has excellent tumor targeting capacity and facilitates inclusion of a hydrophobic anticancer agent and can be combined with fore infrared ray fluorescent material. Therefore, this conjugate can be effectively used for the production of a novel nano-particle contrast agent or a nano-particle drug delivery system for the diagnosis and treatment of cancer.08-19-2010
20110182823Compositions and methods for in vivo evaluation of bioluminescence - Compositions and methods are described for normalizing a bioluminescent signal in a live animal.07-28-2011
20120315220Compounds for Targeting Endothelial Cells, Compositions Containing the Same and Methods for Their Use - The present invention provides compounds for targeting endothelial cells, tumor cells or other cells that express the NP-1 receptor, compositions containing the same and methods for their use. Additionally, the present invention includes diagnostic, therapeutic and radiotherapeutic compositions useful for visualization, therapy or radiotherapy.12-13-2012
20100266507LUMINESCENT COMPOUNDS - Luminescent reporter compounds that are rotaxanes having the structure10-21-2010
20120134930Pyrazine Derivatives for Bioconjugation - Provided are compounds and compositions of general Formula IX: E1-L-Ar-X-PA, that may be utilized in bioconjugation procedures, where Ar is a chromophore and PA is a functional group capable of being attached to any bioactive molecule of interest. The present invention provides Formulas I-III that are capable of being attached to a bioactive vector for the selective delivery of said photoactive pyrazine derivatives to a desired biological target.05-31-2012
20120076735Nanoparticles for Extravascular Administration - Disclosed are drug delivery systems and methods for extravascular administration of drug, vaccine, and/or diagnostic agents, for use in research and medical applications.03-29-2012
20090130024Biocompatible N, N-Disubstituted Sulfonamide-Containing Fluorescent Dye Labels - This invention relates to new fluorescent chemical entities, especially fluorescent molecules that comprise biocompatible N,N-disubstituted sulfonamide fluorochromes. This invention also relates to the corresponding reactive versions of such molecules. This invention also relates to the corresponding conjugates with moieties such as peptides, proteins, various biomolecules, carbocyclic and heterocyclic compounds, sugars, and their uses thereof.05-21-2009
20100047179TARGETED SPLIT BIOMOLECULAR CONJUGATES FOR THE TREATMENT OF DISEASES, MALIGNANCIES AND DISORDERS, AND METHODS OF THEIR PRODUCTION - The present invention is directed to compositions and methods for the production of split-biomolecular conjugates for the directed targeting of nucleic acids and polypeptides. More preferably, the compositions and methods allow for the use of the split biomolecular conjugates for the treatment of diseases, malignancies, disorders and screening. In some embodiments, the split biomolecular conjugates comprise split effector protein fragments conjugated to a probe, and interaction of both probes with a target nucleic acid or target polypeptide, such as a pathogenic nucleic acid sequence or pathogenic protein, brings a the split-effector fragments together to facilitate the reassembly of the effector molecule. Depending on the effector molecule, the protein complementation results in a cellular effect, in particular for the treatment of diseases, malignancies and disorders.02-25-2010
20120177578COMPOSITIONS, METHODS, AND SYSTEMS COMPRISING FLUOROUS-SOLUBLE POLYMERS - The present invention generally relates to compositions, methods, and systems comprising polymers that are fluorous-soluble and/or organize at interfaces between a fluorous phase and a non-fluorous phase. In some embodiments, emulsions or films are provided comprising a polymer. The polymers, emulsions, and films can be used in many applications, including for determining, treating, and/or imaging a condition and/or disease in a subject. The polymer may also be incorporated into various optoelectronic device such as photovoltaic cells, organic light-emitting diodes, organic field effect transistors, or the like. In some embodiments, the polymers comprise pi-conjugated backbones, and in some cases, are highly emissive.07-12-2012
20100272650SEMICONDUCTOR NANOPARTICLE, AND FLUORESCENT LABELING SUBSTANCE AND MOLECULE/CELL IMAGING METHOD BY USE THEREOF - There is provided semiconductor nanoparticles which exhibit enhanced emission efficiency, excellent emission intensity, reduced variation range of emission characteristics among lots and among particles and are excellent in stability and reproducibility. There is further provided a fluorescent labeling agent and molecule/cell imaging method by use of the same. Semiconductor nanoparticles having an average particle size of 1 to 20 nm is disclosed, comprising a dopant of a heteroatom which is identical in valence electron configuration with a main component atom forming the semiconductor nanoparticles or an atomic pair of the heteroatom, and the dopant is distributed on or near a surface of the semiconductor nanoparticles.10-28-2010
20100303729CYANOCHROME FLUOROPHORES - Genetically-engineered cyanochrome fluorophore molecules (fluorophores) with increased fluorescence and with absorbing fluorescence in the blue and green (blue/green) portion of the light spectrum are provided. These fluorophores are derived from the domains of phytochromes, and in particular cyanobacterial phytochromes. Methods for generating these fluorophores and various applications of these fluorophores are also provided.12-02-2010
20090060843Non-Invasive In Vivo Imaging and Methods for Treating Type I Diabetes - The present invention provides novel drug discovery platforms and methods for treating type I diabetes.03-05-2009
20120225021STABLE COLLOIDAL GOLD NANOPARTICLES WITH CONTROLLABLE SURFACE MODIFICATION AND FUNCTIONALIZATION - In the present invention, a method of producing stable bare colloidal gold nanoparticles is disclosed. The nanoparticles can subsequently be subjected to partial or full surface modification. The method comprises preparation of colloidal gold nanoparticles in a liquid by employing a top-down nanofabrication method using bulk gold as a source material. The surface modification of these nanoparticles is carried out by adding one or multiple types of ligands each containing functional groups which exhibit affinity for gold nanoparticle surfaces to produce the conjugates. Because of the high efficiency and excellent stability of the nanoparticles produced by this method, the fabricated gold nanoparticle conjugates can have surface coverage with functional ligands which can be tuned to be any percent value between 0 and 100%.09-06-2012
20120258048OPTICAL FLUORESCENT IMAGING - Compounds and methods are disclosed that are useful for noninvasive imaging in the near-infrared (NIR) spectral range. The NIR is highly sensitive for tumor detection and tracking. The application discloses targeting a tumor-enriched cell surface receptor with a ligand-conjugated fluorescent probe, which specifically allows detection of the tumor relative to the negligible animal autofluorescence.10-11-2012
20120230918NON-INVASIVE IN VIVO OPTICAL IMAGING METHOD - The present invention relates to a non-invasive method of determining the presence, quantifying the blood level, and/or monitoring or determining the blood clearance of a fluorescent analyte which comprises a fluorescent entity and a second entity, in the blood of a subject, comprising or consisting of the steps: (a) directing excitation light of at least one predetermined wavelength onto a delineated region comprising at least a portion of the pupil of said subject, to excite the fluorescent entity, (b) receiving light emitted from said fluorescent analyte with a wavelength distinguishable from the predetermined wavelength of (a), through the eye of said subject, thereby determining the presence, quantifying the blood level, and/or monitoring or determining the blood clearance of said fluorescent analyte in the blood of said subject. The present invention further relates to a fluorescent analyte or fluorescent label as defined in any one of the preceding claims for use in any one of the preceding methods. The present invention furthermore relates to the use of a fluorescent analyte or fluorescent label as defined in any one of the preceding claims for the preparation of a diagnostic composition which is to be employed in any one of the preceding methods. The present invention furthermore relates to a device for use in any of the methods defined herein.09-13-2012
20110123456HOLLOW BIODEGRADABLE NANOSPHERES AND NANOSHELLS FOR DELIVERY OF THERAPEUTIC AND/OR IMAGING MOLECULES - A polymeric hollow nanoshell or nanosphere for release of an agent is described, wherein the hollow nanosphere comprises at least one biodegradable polymer, characterised in that the polymer is cross-linked. The biodegradable mono-disperse nanospheres described are suitable for use as carriers of biomolecules, therapeutic agents and/or imaging agents.05-26-2011
20120269734Self-Illuminating Dot Systems and Methods of Use Thereof - Generally, aspects of the present disclosure are directed to conjugate systems, self-illuminating quantum dot conjugates, methods of detecting a target in a host, methods of treating a disease in a host, and the like.10-25-2012
20120321563Carbonic Anhydrase Targeting Agents and Methods of Using Same - The invention provides agents that target carbonic anhydrase, which can be used as imaging agents or therapeutic agents. The agents can be used to image tumor hypoxia as well as other physiological processes in a subject.12-20-2012
20100233092IN-VIVO MONITORING OF CIRCULATING APOPTOTIC CELLS - The present invention provides methods and systems for performing in vivo flow cytometry. In one embodiments, selected circulating cells of interest of a subject are labeled with fluorescent probe molecules. The labeled cells are irradiated in-vivo so as to excite the fluorescent probes, and the radiation emitted by the excited probes is detected, preferably confocally. The detected radiation is then analyzed to derive desired information, such as relative cell count, of the cells of interest. In some embodiments, the circulating cells comprise apoptotic cells whose detection can allow, e.g., non-invasive monitoring of the efficacy of a cancer treatment, such as an anti-tumor or an anti-angiogenic therapy.09-16-2010
20120321562NICOTINIC ACID AND PICOLINIC ACID DERIVED NEAR-INFRARED FLUOROPHORES - This invention relates to new fluorescent chemical entities, including fluorescent molecules that comprise a carboxyl or carbonyl functionalized pyridine moiety. This invention also relates to the corresponding reactive versions of such molecules. This invention also relates to the corresponding conjugates with moieties such as peptides, proteins, various biomolecules, carbocyclic and heterocyclic compounds, sugars, and their uses thereof.12-20-2012
20120328530TOLUIDINE BLUE DERIVATIVES AS PHOTOSENSITISING COMPOUNDS - A compound of formula (III), or a pharmaceutically acceptable derivative thereof for use in a method of combating and/or detecting a pathogen and/or tumour cells; wherein X is selected from O, S and Se; each of R12-27-2012
20100215585DYES AND PRECURSORS AND CONJUGATES THEREOF - Novel dyes, precursors to novel dyes, and conjugates of the novel dyes are disclosed, as well as methods of making and using the same.08-26-2010
20120100078Pyrazine Derivatives and Uses Thereof in Renal Monitoring - The present invention relates to pyrazine derivatives such as those represented by Formulas I and II below.04-26-2012
20120100077MIXTURE OF AMPHIPATHIC MOLECULES AND METHOD FOR MODIFYING CELL MEMBRANES BY MEANS OF FUSION - Disclosed is a mixture of amphipathic molecules and a method for modifying cells in vivo by way of membrane fusion with these molecules.04-26-2012
20100202975NOVEL FLUORESCENT DERIVATIVES OF POLYAMINES, METHOD FOR PREPARING SAME AND APPLICATIONS THEREOF AS DIAGNOSIS TOOLS IN THE TREATMENT OF CANCEROUS TUMORS - The invention relates to novel fluorescent derivatives of polyamines having a benzoxadiazole group, to a method for preparing the same and to the use thereof as diagnosis tools for emphasising the polyamine transport system in cancerous cells in order to adapt the treatment thereof, and thus for selecting patients carrying such tumours in order to adapt their treatment. The derivatives are of the formula (I) or a pharmaceutically acceptable salt thereof, in which: R08-12-2010
20130011337THERAPEUTIC AGENT AND DIAGNOSTIC AGENT FOR MITOCHONDRIAL DYSFUNCTION BRAIN DISEASES - To provide a therapeutic agent and a diagnostic agent for mitochondrial dysfunction brain diseases including cerebral infarction as a representative.01-10-2013
20130017154Uniform Fluorescent Microsphere with Hydrophobic Surfaces - Fluorescent microspheres for the measurement of blood flow are provided. The microspheres are substantially uniform in diameter and have a hydrophobic surface, which allows them to circulate more freely throughout bloodstream, while reducing immunogenicity, particle aggregation and bioaccumulation. The hydrophobic surface on each microsphere is generally comprised of polymeric material having a limited surface charge.01-17-2013
20110158913Antisense and pretargeting optical imaging - The present invention relates, in part, to detectably labeled oligomer duplexes and their use in optical imaging, including, in vivo optical imaging. The invention includes methods of optical imaging including in vivo pretargeting methods and in vivo antisense optical imaging methods.06-30-2011
20130171074TARGETING COMPOUNDS - The present invention provides antibody targeting compounds in which the specificity of the antibody has been reprogrammed by covalently or noncovalently linking a targeting agent to the combining site of an antibody. By this approach, the covalently modified antibody takes on the binding specificity of the targeting agent. The compound may have biological activity provided by the targeting agent or by a separate biological agent. Various uses of the invention compounds are provided.07-04-2013
20090041668Non-invasive localization of a light-emitting conjugate in a mammal - Methods and compositions for detecting and localizing light originating from a mammal are disclosed. Also disclosed are methods for targeting light emission to selected regions, as well as for tracking entities within the mammal. In addition, animal models for disease states are disclosed, as are methods for localizing and tracking the progression of disease or a pathogen within the animal, and for screening putative therapeutic compounds effective to inhibit the disease or pathogen.02-12-2009
20080226563Non-invasive localization of a light-emitting conjugate in a mammal - Methods and compositions for detecting and localizing light originating from a mammal are disclosed. Also disclosed are methods for targeting light emission to selected regions, as well as for tracking entities within the mammal. In addition, animal models for disease states are disclosed, as are methods for localizing and tracking the progression of disease or a pathogen within the animal, and for screening putative therapeutic compounds effective to inhibit the disease or pathogen.09-18-2008
20080226562Biocompatible fluorescent metal oxide nanoparticles - The invention relates to highly fluorescent metal oxide nanoparticles to which biomolecules and other compounds can be chemically linked to form biocompatible, stable optical imaging agents for in vitro and in vivo applications. The fluorescent metal oxide nanoparticles may also be used for magnetic resonance imaging (MRI), thus providing a multi modality imaging agent.09-18-2008
20110262363GLUCOSE BIOSENSOR SYSTEM COUPLED WITH AN ANTI-INFLAMMATORY MODULE AND METHODS FOR USING THE SAME - Disclosed are apparatuses for detecting glucose levels in a subject. The apparatuses include a glucose sensor coupled with an anti-inflammatory module. The apparatus is configured to monitor blood glucose by detecting the fluorescence generated by the sensor and simultaneously reduce the tissue inflammation reaction. Also disclosed are biosensor systems including the apparatuses and methods of using the biosensor systems.10-27-2011
20130142733MULTIFUNCTIONAL DEGRADABLE NANOPARTICLES WITH CONTROL OVER SIZE AND FUNCTIONALITIES - In one aspect, the invention relates to polymers, crosslinked polymers, functionalized polymers, nanoparticles, and functionalized nanoparticles and methods of making and using same. In one aspect, the invention relates to degradable polymers and degradable nanoparticles. In one aspect, the invention relates to methods of preparing degradable nanoparticles and, more specifically, methods of controlling particle size during the preparation of degradable nanoparticles. In one aspect, the degradable nanoparticles are useful for complexing, delivering, and releasing payloads, including pharmaceutically active payloads. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.06-06-2013
20130142734TARGETED DELIVERY SYSTEMS FOR DIAGNOSTIC APPLICATIONS - Targeting of imaging probes specifically to diseased tissues such as cancer is attractive because it potentially allows the improvement of tumor detection. One of the problems associated with conventional, low molecular weight imaging probes is the limited tumor:background ratio. To circumvent this, imaging probes may be conjugated to polymeric carriers to target solid tumors by either passive accumulation of macromolecules into tumor tissues due to the “enhanced permeability and retention” effect (EPR effect) or active targeting through the incorporation of cell-specific recognition ligands that mediate binding to cancer-specific antigens. This invention describes an innovative targeting strategy for the selective delivery of diagnostic agents into solid tumors by means of polymer-NIR fluorochrome conjugates modified with targeting ligands that bind to antigens or receptors that are uniquely expressed or over-expressed on the target cells relative to normal tissues.06-06-2013
20100040554CONJUGATES OF PHOTO-ACTIVATABLE DYES - A new class of photoactivatable dyes provides the ability to study cell-cell communication in live animals non-invasively with high spatiotemporal resolution. The compositions are made up of a macromolecule, a caging group, and a coumarin dye. Upon photolysis, the coumarin dye is released from the macromolecule caging group complex and is freely diffusible in cells and between cells. The compositions are retained in cells very well, having no observable side effects, no susceptibility to metabolism, and the ability to generate bright fluorescence signals after photolysis. Because of their high loading capacity and long cellular retention, they can be selectively uncaged in specific cells.02-18-2010
20130202537COMPOSITIONS FOR LABELING NERVES AND METHODS OF USE - The present invention provides methods for guiding preservation of neurons or nerves during surgery by administering a fluorescently-labeled peptide that associates with (e.g., specifically binds to) the neurons or nerves. The invention further provides targeting molecules of fluorescently-labeled peptides or aptamers that associate with (e.g., specifically bind to) neurons or nerves and for compositions thereof.08-08-2013
20120251458Dyes for Membranes and Biological Structures - The present invention relates to the use of one or more natural dyes, alone or in combination with other dyes for preparation of a composition to stain membranes and biological structures, in order to facilitate their identification during surgical procedures. The present invention relates to the use of one or more natural dyes, alone or in combination with other dyes, to stain membranes and biological structures, in order to facilitate their identification during surgical procedures.10-04-2012
20090304598FLUORESCENT MEMBRANE INTERCALATING PROBES AND METHODS FOR THEIR USE - The invention relates to a family of dyes which fluoresce in the UV-VIS, far red and near infrared wavelengths of the spectrum and possess asymmetric lipophilic alkyl chains. The dyes of the invention are soluble in commercially available membrane staining dyes, are useful as probes for rapidly staining lipophilic structures such as membranes in cells or isolated from cells, and are well-retained therein. Methods of utilizing the dyes to detect stained cells both in vivo and in vitro are also disclosed.12-10-2009
20130101519Diagnostic Method for Atherosclerosis - The invention relates to a method of identifying/monitoring active atherosclerotic plaques associated with blood vessel walls wherein the plaques comprise activated macrophages having accessible binding sites for a ligand. The method comprises the steps of administering to a patient being evaluated for atherosclerosis an effective amount of a composition comprising a conjugate of a ligand and a chromophore capable of emitting light under predetermined conditions, allowing sufficient time for the ligand conjugate to bind to the activated macrophages, subjecting the blood vessels to the predetermined conditions using a catheter-based device, and identifying active plaques by detecting light emitted by the chromophore using a catheter-based device or by using an external imaging technique. The invention also relates to a similar method wherein a chemical moiety capable of emitting radiation is conjugated to the ligand.04-25-2013
20130101517DEVELOPMENT OF PHOTOSTABLE NEAR-IR CYANINE DYES FOR IN VIVO IMAGING - A compound of structural formula (I):04-25-2013
20130101518METHOD AND APPARATUS FOR KIDNEY FUNCTION ANALYSIS - A method and apparatus for determining physiological data related to an animal, such as kidney diagnostics data, is provided. The method includes injecting a mixture of a first and a second molecule into an animal (e.g., a human patient), determining a molecular ratio of the molecules, and determining the physiological data based on the molecular ratio. The apparatus includes a number of finger receiving apertures, a light generation circuit, a light detection circuit, a pulse counting circuit, and a user interface.04-25-2013
20130142732RECOMBINANT FLUORESCENT NANOPARTICLES - A recombinant fluorescent protein nanoparticle having high fluorescence intensity and a method of detecting a target material using the same are provided. The protein nanoparticle has higher fluorescence intensity than a fluorescent protein, and is resistant to denaturation of the fluorescent protein at room temperature, thereby having higher structural stability than the fluorescent protein itself. In addition, since a self-assembled protein is used as a fusion partner of the fluorescent protein, the protein nanoparticle is biocompatible and safe. Moreover, when a linker peptide is additionally inserted into the protein nanoparticle, a suitable distance between the self-assembled protein and the fluorescent protein is maintained, thereby considerably increasing fluorescence intensity of the protein nanoparticle. The probe-binding protein nanoparticle can control distances between the fluorescent proteins on the surface thereof, thereby maximizing fluorescence intensity.06-06-2013
20110223111CALCIUM CARBONATE MICROSTRUCTURES USEFUL IN ENCAPSULATION APPLICATIONS AND A PROCESS FOR THE PREPARATION THEREOF - A facile method to synthesize stable calcium carbonate microstructures is demonstrated which allows in situ encapsulation of sensitive molecules like drugs. The methodology involves a macromolecular assembly of anionic polypeptide with cationic peptide oligomer to concurrently template and hold to stabilize the mineralized structure. The heterogeneously distributed mixture of anionic and cationic residues in the macromolecular assembly, similar to that is found in natural systems assists in recognizing and coassembling Ca09-15-2011
20130149251OPTICAL SENSOR CONJUGATES FOR DETECTING REACTIVE OXYGEN AND/OR REACTIVE NITROGEN SPECIES IN VIVO - The present invention provides methods and compositions based on optical sensor conjugates that are useful for detecting reactive oxygen, reactive nitrogen, or both species that are a direct result of inflammation caused by tissue damage.06-13-2013
20120276015Optical in vivo Imaging Contrast Agents and Methods of Use - Provided is an optical in vivo contrast agent comprising a fluorescent polymeric microsphere, wherein the micro-sphere is impregnated with a dye having an excitation and emission spectrum compatible with in vivo imaging, and wherein the microsphere is coated with a block copolymer.11-01-2012
20120276014MEASUREMENT OF BODY FLUID VOLUMES - The present invention is related generally to measurement of body fluid volumes in an animal subject. The body fluid volumes of interest include extracellular fluid volume (ECFV), total vascular plasma volume (TVPV) and interstitial fluid volume (IFV). The methods are especially beneficial for subjects suffering from renal failure and particularly those undergoing renal dialysis. ECFV can be measured by administering a first molecule which is non-metabolized and permeable to vessel walls of the vascular system wherein the first molecule is distributed within the total vascular space as well as the interstitial space. TVPV can be measured by administering a second molecule which is non-metabolized and impermeable to vessel walls of the vascular system wherein the second molecule is distributed within only the vascular space. IFV can then be calculated using the equation IFV=ECFV−TVPV.11-01-2012
20130149252SWITCHING FLUORESCENT NANOPARTICLE PROBE AND FLUORESCENT PARTICLE IMAGING METHOD USING SAME - The present invention provides a novel fluorescent nanoparticle imaging probe having a switching function (a function to quench a fluorescent dye during nanoparticle preparation, and emit fluorescence during imaging). A switching fluorescent nanoparticle probe comprising: a molecular assembly composed of an amphiphilic block polymer having a hydrophilic block chain and a hydrophobic block chain; and a fluorescent dye encapsulated in the molecular assembly, wherein (a) the hydrophilic block chain comprises, as an essential hydrophilic structural unit, a unit selected from a sarcosine unit and an alkylene oxide unit, (b) the hydrophobic block chain comprises, as an essential hydrophobic structural unit, a unit selected from the group consisting of an amino acid unit and a hydroxylic acid unit, and (c) the fluorescent dye is a cyanine compound represented by the formula (I):06-13-2013
20130121925OPTICAL DETERMINATION OF GLUCOSE UTILIZING BORONIC ACID ADDUCTS - The present invention concerns an improved optical method and optical sensing device for determining the levels of polyhydroxyl-substituted organic molecules in vitro and/or in vivo in aqueous media. The range of detection is between about 400 and 800 nm. In particular, a sensory devise is implemented in a mammal to determine sugar levels. Specifically, a dye is combined with a conjugated nitrogen-containing heterocyclic aromatic boronic acid-substituted bis-onium compound in the presence of a sugar, such as fructose or glucose. The viologens are preferred as the aromatic conjugated nitrogen-containing boronic acid substituted compounds. The method is useful to determine sugar levels in a human being.05-16-2013
20100074847Chromophore Probes for Optical Imaging - Chromophore probes that are capable of being taken up by, retained by or bound to a biocompatible molecule to form an imaging construct are provided. Various activation strategies of the resulting imaging construct are also provided.03-25-2010
20130156705BIVALENT MULTIFUNCTIONAL LIGANDS TARGETING A[BETA] OLIGOMERS AS TREATMENT FOR ALZHEIMER'S DISEASE - Bivalent multifunctional Aβ oligomerization inhibitors (BMAOIs) that target multiple risk factors involved in Alzheimer's disease are provided. The BMAOIs are useful for the treatment and/or prevention of Alzheimer's disease, as well as for diagnostic imaging of Aβ plaques in brain tissue. The BMAOIs comprise i) an Aβ oligomer (ApO)-inhibitor moiety which may have antioxidant activity (e.g. curcumin, curcumin derivatives, curcumin hybrids, resveratrol, etc.); ii) a cell membrane/lipid raft (CM/LR) anchoring moiety (e.g. cholesterol, cholesterylamine, a steroid, etc.); and iii) a spacer or linker moiety that stably links i)06-20-2013
20130183247FLUORESCENT CYANINE-POLYAMINE DERIVATIVES AS A DIAGNOSTIC PROBE - The invention relates to fluorescent derivatives of cyanines conjugated with a polyamine group, having formula (I), or a pharmaceutically acceptable salt thereof. The invention also relates to the method for preparing said derivatives, diagnostic compositions containing same and the use thereof as a diagnostic probe for the detection of cancer tumours, in particular in vivo.07-18-2013
20130121926DYE COMPOSITIONS AND DYE SYNTHESES - The present invention relates to sulfonated optical dye compositions, especially dyes suitable for biological applications in vitro, and for in vivo imaging. Improved dye compositions and intermediates are provided, which enable the suppression of undesirable newly-identified impurities. Also provided is the use of the improved dye compositions in the preparation of conjugates with biological targeting molecules.05-16-2013
20130121924FLUORESCENCE DETECTION OF POISON OAK OIL - The invention herein disclosed provides for compositions, methods for synthesizing said compositions, and methods for using said compositions, wherein the compositions and methods may be used to bind to and/or deactivate a poison oak oil, such as urushiol. The compositions and methods can be used to treat and/or reduce an inflammatory reaction and/or hypersensitivity to natural compounds found in poison oak, poison ivy, poison sumac, mango, lac tree, and cashew nut.05-16-2013
20130189188TEMPERATURE-MODULATED FLUORESCENCE TOMOGRAPHY - Aspects of the disclosure relate to fluorescence imaging, and more particularly to the use of temperature modulation in a tissue site with a modulator such as high intensity focused ultrasound to modulate the emission signal emitted by temperature-sensitive optical fluorescence reporters.07-25-2013
20120027689METHODS AND COMPOSITIONS FOR ALTERING PHOTOPHYSICAL PROPERITES OF FLUOROPHORES VIA PROXIMAL QUENCHING - The invention is directed to fluorophore-containing compositions and configurations wherein proximity between the fluorophore and one or more protective agents (PAs) modifies the lifetime of fluorescent and/or dark states, their frequency of occurrence, and the total lifetime of fluorescence in order to appropriately modify the photophysical characteristics of the fluorophore. The invention is also directed to methods that utilize these compositions and configurations.02-02-2012
20130195765METHOD FOR TREATING AND DIAGNOSING CANCER BY USING CELL-DERIVED MICROVESICLES - Disclosed is a method for the treatment and/or diagnosis of cancer, using bacterial cell-derived microvesicles, which is highly effective in cancer therapy with a significant reduction in side effects. Also, a method is provided for delivering of a drug therapeutic or diagnostic for a disease, using bacterial cell-derived microvesicles loaded with the drug, thereby treating and diagnosing the disease effectively and specifically.08-01-2013
20130195764Nanoparticle Targeting to Ischemia for Imaging and Therapy - The invention provides compositions and methods that provide a solution to the difficulties in diagnosing ischemia, e.g., identifying specific affected anatomical areas, and treating ischemic tissue so as to minimize damage and promote healing of damaged tissue in a subject such as a human or other animal.08-01-2013
20130202536FLUOROPHORE CHELATED LANTHANIDE LUMINESCENT PROBES WITH IMPROVED QUANTUM EFFICIENCY - The invention relates to novel luminescent compositions of matter containing a fluorophore, synthetic methods for making the compositions, macromolecular conjugates of the compositions, and the use of the compositions in various methods of detection. The invention also provides kits containing the compositions and their conjugates for use in the methods of detection.08-08-2013
20120076736HOST SUPPORTED GENETIC BIOSENSORS - The present invention relates to an in vivo method of monitoring an analyte in a subject. This method involves providing an expression vector that encodes a biosensor molecule, the biosensor molecule comprising an analyte binding domain and a signal domain. The biosensor molecule produces a signal from the signal domain upon binding of the analyte by the analyte binding domain. The signal is detectable by a non-invasive means. The expression vector is introduced locally into in vivo cells of a subject under conditions effective to express the biosensor molecule in the cells. The signal from the expressed biosensor molecule is detected by a non-invasive means, thereby monitoring the analyte in the subject in vivo.03-29-2012
20130095042SILICA-BASED NANOPARTICLES AND METHODS OF STIMULATING BONE FORMATION AND SUPPRESSING BONE RESORPTION THROUGH MODULATION OF NF-KB - Osteoporosis, is an exceedingly common malady that leads to bone fracture and results from an imbalance in the rate of osteoblastic bone formation with respect to osteoclastic bone degradation. Nanotechnology has raised exciting possibilities for the development of novel therapeutic agents. Embodiments of the disclosure provide silica-based fluorescent nanoparticles endowed with natural bone targeting capabilities and expressing potent pro-osteoblastogenic and concomitant anti-osteoclastogenic activities in vitro and the capacity to increase bone mineral density in vivo. Embodiments of the disclosure can achieve their stimulatory effects on osteoblasts, and inhibitory effects on osteoclasts, in part by suppressing NF-KB signal transduction. Embodiments of the present disclosure provide for derivatives of silica-based nanoparticles that represent a novel class of dual anti-catabolic and pro-anabolic agents that may be applicable to the amelioration of numerous osteoporotic conditions.04-18-2013
20130209368NEAR INFRARED FLUORESCENT PARTICLES AND USES THEREOF - The present invention provides particles comprising either a water-soluble polymer or a phospholipid, wherein at least one near infrared (NIR) fluorescent probe and optionally at least one active agent such as a targeting moiety, capable of selectively recognizing a particular cellular marker, are non-covalently bound to the outer surface of the particles. Pharmaceutical compositions comprising these particles may be used, inter alia, for detection and treatment of tumors in the gastrointestinal tract08-15-2013
20130209367PARTICLE AND CONTRAST AGENT HAVING THE PARTICLE - There is provided an ICG-loaded polymer nanoparticle that is dynamically stable, prevents the leakage of contained ICG and the resulting discoloration, and has a high molar absorbance coefficient. The particle contains a hydrophilic dye having a sulfonate group and a hydrophobic polymer, and the particle further contains at least one of a lipid having a positively charged region, a nicotinic acid derivative and a thiamine derivative.08-15-2013

Patent applications in class Diagnostic or test agent produces in vivo fluorescence

Patent applications in all subclasses Diagnostic or test agent produces in vivo fluorescence